

CURRICULUM VITAE

CLEMENT KAR-MAN CHAN, M.D., F.A.C.S.

SPECIALTY: Vitreoretinal Ophthalmology
Medical and surgical management of diseases of the retina, macula, and vitreous

CONTACT & OFFICE ADDRESSES:

1. Southern California Desert Retina Consultants
 - University Park, 36-949 Cook Street, Suite 101, Palm Desert, CA 92211
(760) 340-2394
FAX: (760)340-2369
 - 340 S. Farrell Drive, Suite A-105 Palm Springs, CA 92262 (760) 327-6225
2. Inland Retina Consultants
 - Brockton Center, 6216 Brockton Avenue, Suite 214, Riverside, CA 92505
(951) 686-1190
3. Mailing Address: PO Box 2467 Palm Springs, CA 92263

EDUCATION & TRAINING:

James Weaver Nicoson Scholarship Award to University of California at Berkeley 06/73

1. College: Pacific Union College, One Angwin Ave, Angwin, CA 94508 09/1973 – 03/1977
 - California State Scholarship (**4-year full scholarship**)
 - Summer 1976: California Heart Assn. Summer Student Research Fellowship: “Basic science research of calcium metabolism in sarcoplasmic reticulum of skeletal muscles”; Univ. of the Pacific, San Francisco, CA with Dr. G. Inesi
 - First in class standing in: Organic chemistry, biochemistry, physical chemistry, neuroanatomy, zoology, and mammalian anatomy.
 - Lab instructor: Organic Chemistry, biochemistry, mammalian anatomy
 - President of Chinese Club 1975-1976
 - BS degree in biochemistry; **Magna Cum Laude** – GPA 3.97
2. Medical School: Loma Linda University School of Medicine Loma Linda, CA 92350
11175 Campus Street, CP A-1108, Loma Linda, CA 92350
03/1977 – 06/1980 M.D. degree; Cumulative Class standing in upper 10%
California State Fellowship (**full scholarship for medical school**)
Alpha Omega Alpha Medical Honor Society 1980
3. Internship: Flexible Internship 07/1980 – 06/1981
White Memorial Medical Center, 1720 César Chávez Ave Los Angeles, CA 90033

4. Residency: Ophthalmology 07/1981 – 06/1984
Loma Linda University School of Medicine, Dept. of Ophthalmology
Faculty Medical Offices, Suite 1800, 11370 Anderson Street Loma Linda, CA 92354
5. Fellowship: Retina-Vitreous 07/1984 – 12/1985
Washington University, Retina Consultants, Ltd.
Barnes Hospital, One Barnes Hospital Plaza St. Louis, MO 63110
Inquiries to: Barnes Retina Institute 600 S. Brentwood, Suite 800, St. Louis, MO 63144
6. Post-fellowship: Steve Charles, M.D. 12/1985 – 03/1986
Charles Retina Institute 6401 Poplar Ave. Ste. 190, Memphis, TN 38119

BOARD CERTIFICATION: American Board of Ophthalmology Oct 1985

MEDICAL LICENSURE: California 1981

PROFESSIONAL POSITIONS:

1. Director of Retina / Vitreous Service: Assistant Professor Department of Ophthalmology, Loma Linda University, Loma Linda, CA. 07/01/1986 – 06/30/1989
2. Founder, President,
3. and Medical Director: Southern California Desert Retina Consultants, vitreoretinal group practice in Palm Springs, CA 07/01/1989 – Present
4. Medical Director of Inland Retina Consultants (Satellite Offices): San Bernardino and Riverside 01/01/1995 – Present
5. Active medical staff, Desert Regional Medical Center, Palm Springs, CA.

1150 N Indian Canyon Drive Palm Springs, CA 92262 (760) 323-6511
 - Vice Chairman, Institutional Review Board 1993 – 1995.
 - Laser Policy / Safety Committee member 1991 – Present.
 - **Chairman, Ophthalmology section 1995 – 2004.**
6. Consultant, Eisenhower Medical Center, Rancho Mirage, CA.
39-000 Bob Hope Drive, Rancho Mirage, CA 92270 760-340-3911
7. Courtesy medical staff, Loma Linda University Medical Center, Loma Linda, CA.
11234 Anderson Street, Loma Linda, California 92354.
8. Consultant, Riverside Community Hospital, Riverside, CA.
9. Partner physician, Unifeye Vision Partners

ACADEMIC APPOINTMENTS & CONTRIBUTIONS:

1. Assistant Professor, Department of Ophthalmology Loma Linda University, Loma Linda, CA. 07/01/1986 – 06/30/1989
2. Assistant Clinical Professor, Department of Ophthalmology Loma Linda University, Loma Linda, CA. 07/01/1989 – 11/22/1994
3. Associate Clinical Professor, Department of Ophthalmology; Loma Linda University, Loma Linda, CA. 11/22/1994 – 2016.
4. Clinical Professor, Clinician-Scientist Track, Department of Ophthalmology, Loma Linda University, Loma Linda, CA. May 2016- Onward
5. Lecturer for Fluorescein conferences for Ophthalmology Residents and Medical Students at Loma Linda University – quarterly since 1993 to present. **See** end of this CV for partial list of lectures.

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

1. Fellow of American Academy of Ophthalmology
2. American Society of Retinal Specialists
3. **The Retina Society** (2004) (Subspecialty honor society)
4. **Macula Society** (active member, 2012) (Subspecialty honor society)
5. **Club Jules Gonin** (active member, 2012) (Subspecialty honor society)
6. California Association of Ophthalmology
7. California Academy of Eye Physicians and Surgeons
8. Tri-County Eye Society
9. Western Retina Study Club and currently the Pacific Retina Club
10. Paul Cibis Club (Retina)
11. **Fellow of the American College of Surgeons (1995)**
12. American Medical Association
13. California Medical Association

14. California Scholarship Federation (1973)
15. Fellow of American Society for Laser Medicine and Surgery
16. **Alpha Omega Alpha Medical Honor Society**
17. **American Ophthalmological Society (2014)** (specialty honor society)

ACHIEVEMENTS & AWARDS:

1. James Weaver Nicoson Scholarship Award to University of California at Berkeley 06/73
2. **California State Scholarship (4-year full scholarship for college).**
3. Chemical Rubber Co. Freshmen Chemistry Award 06/1974.
4. **California State Fellowship (full scholarship for medical school).**
5. Fellow of American College of Surgeons (F.A.C.S.) 1995
6. Chairman, Ophthalmology Section, Department of Surgery, Desert Regional Medical Center, Palm Springs, CA. 1995 –2004.
7. Medical consultant for NIDEK [Double-frequency YAG (532NM) laser], 1995.
8. American Society of Retina Specialists **Honor (Achievement) Award**, New York City, Aug 2003.
9. **Active membership of The Retina Society** (2004)
10. Consultant for Eyetech, OSI, 2005.
11. Consultant for Novartis Registry, 2005.
12. Consultant for Novartis training session, Henderson, NV. 2005.
13. **American Academy of Ophthalmology (AAO) Honor (Achievement) Award**, Las Vegas, NV, 2005.
14. Consultant for Eyetech, OSI, Consultant meeting, Cannes, France, Sep 9, 2006.
15. American Society of Retina Specialists **Senior Honor (Achievement) Award**, Indian Wells, CA, Dec 2007.
16. Member of organizing committee and abstract grader for 25th (silver anniversary) annual meeting of American Society of Retina Specialists, Indian Wells, CA, Dec 2007.

17. Member of organizing committee and abstract grader for 26th annual meeting of American Society of Retina Specialists, Maui, HI. Oct 2008.
18. Genentech Advisory Board, New York, NY. Dec 06, 2008, Dec04, 2010.
19. Elected as a candidate for **Club Jules Gonin**, Aug 2009; **active membership**, June 2012.
20. Allergan Advisory Board, Atlanta, GA. Sept 12 and 13, 2009., Aug 28, 2010.
21. Faculty (paper presentation), AAO-2010 Retina Subspecialty Day-Panretinal Perspective, Chicago, Ill, Oct 16, 2010.
22. **Jules Gonin Travel Grant (\$2,500) for paper presentation at the XXVII Jules Gonin's meeting in Kyoto, Japan**, Nov 03, 2010.
23. Elected as **Active Member** of the **Macula Society**, October 21, 2011.
24. Guest editor, **Journal of Ophthalmology**, Special issue: *The Unsteady Capsular Bag*, Hindawi Publishing Corporation, 2010-2011
25. Faculty (paper presentation), AAO-2011 Retina Subspecialty Day-The Magical World of Retina, Orlando, Fl, Oct 21, 2011.
26. Member of editorial board of The Scientific World JOURNAL, 2012 to 2016.
27. Marquis Who's Who in Medicine and Healthcare, 2012 listing.
28. 2013 Bryce Young Lecture (Loma Linda University Department of Ophthalmology, Resident Research Day, May 24, 2013)
29. Acceptance for nomination for **American Ophthalmological Society (AOS)** for submission of a thesis, 2013
30. Acceptance of **AOS thesis** and election to **Active Membership** by **American Ophthalmological Society (AOS)**, May 30, 2014; publication of AOS thesis in **Transactions of American Ophthalmological Society, 2014** (Trans Am Ophthalmol Soc 2014;112:160-198)
31. 2016, **Clinical Professor, Clinician Scientist**, Loma Linda University, School of Medicine.
32. **2018 Honored Alumnus**, Alumni Association, School of Medicine, Loma Linda University, Riverside Convention Center, March 4, 2018
33. **American Board of Ophthalmology (ABO)** oral board examiner, 2018 onwards.
34. **American Academy of Ophthalmology (AAO) Senior Achievement Award**, Chicago, IL, 2018.
35. Member of **executive committee** of the **DRCR.net**, 2018 to 2020.

36. Faculty (paper presentation), AAO-2020 Retina Subspecialty Day-, Vision for the Future Las Vegas, NV, Nov 13, 2020.
37. 2022, Palm Springs Life's Top Doctors in Ophthalmology.

SCIENTIFIC REFEREE (PEER REVIEW SERVICE):

1. Peer-reviewed journal, **Ophthalmology** (Blue Journal), (Paul Lichter M.D., Andrew Schachat M.D., Editor-in-Chief) 6
 - Oct 1993
 - Mar 2008
 - Sep 2009
 - Dec 2009
 - April, May 2010
 - May 2012
 - Sept 2016

2. Peer-reviewed journal, **Ophthalmology Retina**
 - January 2018
 - May 2018
 - May 2019
 - March 2020
 - April 2020
 - January 2022
 - July 2022
 - April 2023
 - July 2023 x 2
 - Feb 2024
 - April 2024
 - Sept 2024
 - October/November 2024
 - December 2024

3. Peer-reviewed journal, **RETINA**, (Alexander Brucker, M.D., Editor-in-Chief)
 - 2005 to 2007 (9 times)
 - 2008 to 2009 (16 times)
 - 2010 (7)
 - 2011 (3)
 - 2012 (7)
 - 2013 (8)
 - 2014 (7)
 - 2015 (4)
 - 2016 (8)
 - 2017 (9)

- 2018 (11)
 - 2019 (4)
 - 2020 (13)
 - 2021 (10)
 - 2022 (6)
 - 2023 (8)
 - 2024 (12)
 - 2025 (2)
4. Peer-reviewed journal, **EUROPEAN JOURNAL OF OPHTHALMOLOGY** (Rosario Brancato M.D., Editor-in-Chief); Francesco Bandello, M.D.
- 2008 to 2009 (7 times)
 - 2010 (5)
 - 2011 (2)
 - 2012 (1)

 - 2013 (1)
 - 2014 (1)
 - 2015 (2)
 - 2017 (2)
 - 2018 (3)
 - 2020 (2)
 - 2022 (4)
 - 2023 (4)
5. Peer-reviewed journal, **British Journal of Ophthalmology 2**
- Nov 2005
 - Jun 2008
6. Peer-reviewed journal, **EYE** (Professor Ian Rennie, Professor A. J. Lotery Professor Harminder Dua Editors; Arun Singh M.D., Jose Pulido M.D., Young Kwon M.D., Parwez Hossain M.D., John Heckenlively M.D., Victor Chong, associate and section editors) 13
- 2006 to 2008 (5 times)
 - 2009 (2 times)
 - 2010 (3)
 - 2012 (1)
 - 2013 (1)
 - 2014 (1)
 - 2016 (1)
 - 2017 (1)
7. Peer-reviewed journal, **ACTA OPHTHALMOLOGICA** (official journal of Nordic Ophthalmological societies, European Association for Vision and Eye Research), Professor Einar Stefánsson, Chief editor; Carsten Meyer M.D., associate editor 10
- Aug 2008
 - Nov 2008

- July 2010
 - April 2012
 - June 2012
 - July 2012 X 3
 - May 2013
 - November 2014
8. Peer-reviewed journal, **Canadian Journal of Ophthalmology** (Graham Trope M.D., Editor-in-Chief) 1
- Jul 2007
 - Sept 2023
 - February 2025
9. Peer-reviewed journal, **Journal of Refractive Surgery** (George O. Waring III M.D., Editor-in-Chief)
- 2001
9. Peer-reviewed journal, **Journal of Ophthalmic Surgery and Lasers** (Carmen A. Puliafito, M.D., Editor-in-Chief)
- 2002
10. Peer-reviewed journal, **Indian Journal of Ophthalmology** (Barun K Nayak MD, Editor-in-Chief) 9
- Jan 2009
 - Feb 2009
 - Apr 2009
 - Aug 2009
 - Apr 2010
 - Oct 2010
 - April 2011
 - Dec 2011
 - Jan 2012
11. Peer-reviewed journal, **Retinal Cases and Brief Reports** (Alexander Brucker, M.D., Editor-in-Chief) 5
- Nov 2009
 - Sept 2010
 - Oct 2010
 - Feb 2011
 - Feb 2012
 - Aug 2016
 - Oct 2016
 - June 2017
 - April 2020
 - April 2021
 - December 2021

- March 2023
 - July 2023
 - August 2024
12. Peer-reviewed journal, **Journal of Cataract and Refractive Surgery** (Mamalis, M.D., Editor-in-Chief) 9
- April 2010
 - May 2010
 - April 2011
 - Dec 2011
 - Jan 2012
 - June 2013
 - Sept 2013
 - Feb 2014
 - July 2014
 - 2015
 - Sept 2016
 - January 2018
 - February 2018
 - August 2018
 - January 2021
 - March 2023
13. Peer-reviewed journal, **Journal of Ophthalmology** (Hindawi Publishing Corporation)
- May 2011
14. Peer-reviewed journal, **Archives of Ophthalmology** (Daniel Albert, M.D., Editor-in-Chief; Michael Ip, M.D., Associate Editor)
- June 2011
 - June 2012
 - July 2012
 - Oct 2012
 - Dec 2012
 - June 2013
15. Peer-reviewed journal, **JAMA Ophthalmology** (Neil Bressler, M.D., Editor-in-Chief; Roy Beck, M.D., Associate Editor)
- August 2013 X 2
 - July 2020
 - February 2021
 - May 2023
 - Nov 2023
16. Peer-reviewed journal, **Scientific World Journal** (Hindawi publishing corporation)
- August 2013
 -

17. Peer-reviewed journal, **Diabetes Care**
 - August 2014
 - December 2014 x 2
18. Peer-reviewed journal, **Case Report in Ophthalmological Medicine**
 - April 2016
 - December 2017
 - March 2019
19. Peer-reviewed journal, **International Journal of Retina and Vitreous**
 - February 2017
 - April 2017
 - June 2017 x 2
 - March 2018
 - June 2018
 - Sept 2018
 - Feb 2019
 - Aug 2019
 - Nov 2019
 - June 2021
 - December 2024
20. Peer-reviewed journal, **Clinical and Experimental Ophthalmology**
 - April 2017
 - August 2021
21. Peer-reviewed journal, **American Journal of Ophthalmology Case Reports**
 - March 2017
 - Oct 2017
 - Jan 2018
 - May 2018
 - Jan 2019
 - June 2019
 - May 2020
 - Aug 2020
 - Sept 2020
 - May 2021
 - June 2023
 - Sept 2023
 - Oct 2023
 - Nov 2023
22. Peer-reviewed journal, **Expert Review of Clinical Pharmacology**
 - Sept 2018
23. Peer-reviewed journal, **BioMedical Research**

- Sept 2020
24. **Science Reports**
 - **April 2021**
 - **April 2022**
 - **April 2024**
 - **June 2024**
 25. **Translational vision Science & Technology (TVST)**
 - March 2023
 - August 2023
 - November 2023
 26. **Investigative Ophthalmology & Visual Science (IOVS)**
 - May 2024
 - Sept 2024
 27. **International Ophthalmology**
 - Sept/Oct 2024
 28. **European Journal of Medical Research**
 - December 2024

JOURNAL EDITOR:

Guest editor, **Journal of Ophthalmology**, Special issue: *The Unsteady Capsular Bag*, Hindawi Publishing Corporation, 2010-2011 (Co-editors: Amar Agarwal, **Clement Chan**, Luther Fry, Tim Roberts).

Editorial Board member: The Scientific World JOURNAL, Hindawi Publishing Corporation, October 2011 to 2016; Journal of Ophthalmic Studies May 2017; SciFed Journal of Ocular Biology, 2017, Journal of Ophthalmology Forecast, 2017 onward

RESEARCH ACTIVITIES:

NIH-SPONSORED STUDIES

1. ***Age-Related Eye Disease Study (AREDS)***, AS Lindblad, Ph. D, Potomac, MD
External Co-investigator for **AREDS** investigator (Elman Retina Center, Maryland)
 - 1995 to 2000
2. ***Age-Related Eye Disease Study II (AREDS II)***, lutein, zeaxanthin, and long-chain omega-3 fatty acids in age-related macular degeneration
 - Principal Investigator
 - 2006 and onward

3. ***Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study I***, Phase III trial to assess efficacy and safety of standard care versus triamcinolone acetonide injection for treatment of CRVO and BRVO
 - Principal Investigator
 - **Member of executive writing committee for primary manuscripts.**
 - **Primary and secondary author for secondary manuscripts**
 - May 2004

4. ***Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study II***; a multi-center, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks (Study of comparative treatments for retinal vein occlusion 2 (SCORE 2)).
 - Principal Investigator
 - **Member of protocol development committee**
 - April 2014 onward

NIH's Diabetic Retinopathy Clinical Research Network (DRCR.net), a collaborative network dedicated to multi-center clinical research of diabetic retinopathy, diabetic macular edema and associated conditions, multiple protocols relating to medical and surgical treatments for diabetic retinopathy; DRCR.net supports the identification, design, and implementation of multi-center clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well.

5. ***Intravitreal triamcinolone for diabetic macular edema (Protocol B)***
 - Principal Investigator
 - Oct 2004 to 2008
6. ***Periocular triamcinolone for diabetic macular edema (Protocol E)***
 - Principal Investigator
 - Oct 2004 to 09/30/2005
7. ***Bevacizumab, (Avastin), a phase 2 evaluation of Anti-VEGF Therapy for diabetic macular edema (Protocol H)***
 - Principal Investigator
 - 2006 to 2007
8. ***Subclinical diabetic macular edema study (Protocol G)***
 - Principal Investigator
 - 2006 and onward
9. ***Evaluation of Vitrectomy for diabetic macular edema study (Protocol D)***
 - Principal Investigator
 - 2006 and onward

10. ***An observational study of the development of diabetic macular edema following scatter laser photocoagulation (Protocol F—PRP-DME Study)***
 - Principal Investigator
 - 2006 to 2007
11. ***Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Study (Protocol I)***
 - Principal Investigator
 - 2007 and onward
12. ***Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Study (Protocol J)***
 - Principal Investigator
 - 2007 and onward
13. ***Laser Response Study (Protocol K)***
 - Principal Investigator
 - 2007 to 2008
14. ***An Evaluation of Intravitreal Triamcinolone Acetonide in Individuals with Diabetic Retinopathy Undergoing Cataract Surgery (Protocols P and Q)***
 - Principal Investigator
 - 2009 and onward
15. ***Intravitreal ranibizumab for vitreous hemorrhage from proliferative diabetic retinopathy Study (Protocol N)***
 - Principal Investigator
 - 2010 and onward
16. ***A Phase II evaluation of topical NSAIDs in eyes with non-center involved diabetic macular edema (Protocol R).***
 - Principal Investigator
 - 2011 and onward
17. ***A Phase III evaluation of prompt panretinal photocoagulation (PRP) vs. ranibizumab-deferred panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) Study (Protocol S).***
 - Principal Investigator
 - June 2012 and onward
18. ***A Phase III comparison effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab for diabetic macular edema, a randomized clinical trial (Protocol T).***
 - Principal Investigator
 - April 2013 onward
19. ***Treatment for central-involved diabetic macular edema in eyes with very good visual acuity (Protocol V).***

- Principal Investigator
 - May 2014 to 2020
20. ***Intravitreal anti-VEGF treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk (Protocol W).***
- Principal Investigator
 - May 2016 onward
21. ***A Phase III comparison effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab for diabetic macular edema, a randomized clinical trial (Protocol T)- Follow-up extension study.***
- Principal Investigator
 - May 2018 to 2020
22. ***Aflibercept versus bevacizumab with deferred aflibercept for diabetic macular edema (Protocol AC).***
- Principal Investigator
 - May 2018 onward
23. ***Non-diabetic study: Pneumatic vitreolysis (PVL) with Gas for vitreomacular traction randomized trial: Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction (Protocol AG)***
- Protocol Chair and Principal Investigator
 - October 2018 to March 2020
24. ***Non-diabetic study: Pneumatic vitreolysis (PVL) with Gas for macular hole study (AH): Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH)***
- Principal Investigator
 - October 2018 to March 2020
25. ***DRCR Retina Network (Jaeb Center): A Phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (DME); this randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved DME and good visual acuity.***
- Principal Investigator
 - May 2023 onward

INDEPENDENT RESEARCH:

26. Retrospective review of all cases of ***supplemental photocoagulation on the buckle post scleral buckling as an alternative to surgical revision, Retinal Consultants*** at St. Louis,
- 1968 to 1985

27. Retrospective review of *long term follow-up of patients with intravitreal liquid silicone* performed in St. Louis, including the original group treated by **Cibis** and **Okun**,
 - 1984 to 1985
28. *Family Study of Macular Degeneration*. JM Seddon, M.D., M.S., **Massachusetts Eye and Ear Infirmary**, Boston, MA
 - External Co-investigator
 - 1996 to the present.
29. *Pneumatic retinopexy (trial #2) for treatment of Retinal detachment* (Study chairmen: G. Hilton M.D. and P. Tornambe M.D.)
 - Principal Investigator, self-funding.
 - 1990 to 1995
30. *Innovative techniques in treating dislocated implants* (see publication: An improved Technique for Management of Dislocated posterior Chamber Implants. Ophthalmol: 1992; 99: 51-57)
 - Principal Investigator, self funding
31. *Pharmacological treatment for Choroidal neovascularization* (see publication: The Treatment of Choroidal Neovascular Membranes by Alpha Interferon: An Efficacy and Toxicity Study. Ophthalmol: 1994; 101: 289-300)
 - Principal Investigator, self funding
32. *Innovative method in the treatment of impending and early full-thickness macular holes (Pneumatic detachment of the vitreous)*, (see publication: Treatment of Idiopathic Macular Holes by Induced Posterior Vitreous Detachment. Ophthalmol: 1995; 102; 757-767)
 - Principal Investigator, self funding.
 -
33. *Retinal complications (breaks and retinal detachment) after LASIK*, retrospective and prospective arms
 - Principal Investigator (IRB approved and monitoring, self funding).
 - 1999 to present
34. *Retinal complications (breaks and retinal detachment) after PRK*, retrospective study
 - Principal Investigator (IRB approved and monitoring, self funding).
 - 1999 to present
35. *Macular hole after LASIK and PRK*, retrospective study
 - Principal Investigator (IRB approved and monitoring, self funding).
 - 1999 to present
36. *Intravitreal Triamcinolone acetonide for Central Retinal Vein Occlusion, prospective study*
 - Principal Investigator, (IRB approved and monitoring, self funding).
 - 2001 to present.

37. ***Intravitreal Triamcinolone acetonide for Branch Retinal Vein Occlusion, prospective study***
- Principal Investigator, (IRB approved and monitoring, self funding).
 - 2001 to present.
38. ***Intravitreal Triamcinolone acetonide for persistent Diffuse Diabetic Macular Edema, prospective study***
- Principal Investigator, (IRB approved and monitoring, self funding).
 - 2001 to present.
39. ***Intravitreal Triamcinolone acetonide for Subfoveal Choroidal Neovascularization, prospective study***
- Principal Investigator, (IRB approved and monitoring, self funding).
 - 2001 to present.
40. ***Vitreotomy and Sheathotomy for Branch Retinal Vein Occlusion, prospective study***
- Principal Investigator, (IRB approved and monitoring, self funding).
 - 2001 to present.
41. ***Radial Optic Neurotomy for Central Retinal Vein Occlusion, prospective study***
- Principal Investigator, (IRB approved and monitoring, self funding).
 - 2001 to present.
42. ***Avastin for choroidal neovascularization associated w/ AMD & other conditions, off-label use.***
- Principal Investigator, IRB monitored, self-funding.
 - Jan 2006 to present
43. ***Avastin for macular edema associated with diabetic retinopathy, branch and central retinal vein occlusion, and other conditions, off-label use.***
- Principal Investigator, IRB monitored, self- funding.
 - Jan 2006 to present
44. ***Multi-center retrospective study on RPE tears associated with intravitreal bevacizumab (AvastinTM) for neovascular AMD.*** Co-investigators and study centers: Carsten Meyer, Marburg, Germany, Jeffrey Gross, Columbia, South Carolina; Prema Abraham, Rapid City, South Dakota; Gregg Kokame, Aiea, Hawaii; Asha Nuthi and Steven Lin, Palm Springs, California; Michael Rauser, Loma Linda, California; Peter Kaiser, Cleveland, Ohio
- Principal Investigator, self-funding.
 - 2005- 2006.
45. Investigator-sponsored trial (IND number from FDA):
 Part 1: (***Intravitreal ranibizumab (high dose [2.0 mg vs. conventional [0.5 mg]] for vascularized pigment epithelial detachment associated with age-related macular degeneration***). (<http://www.clinicaltrials.gov> Registration Number: NCT00749021; Genentech Grant FVF4332s), (awarded budget: \$419,240; additional funding from Owen Locke Memorial Foundation: \$100,000.)

Part 2: **Genetic study (DNA extraction and genotyping)** for single nucleotide polymorphisms (SNP) for genes associated with vascular endothelium growth factor, complement Factor H, Factor B, Factor 2, Factor C3, and Factor C5, etc., (awarded budget: \$141,802).

- Principal Investigator, Independent project approved and **funded by Genentech**,
 - Sept 2008-2011 (**Part 1**)
 - Aug 2011-2013 (**Part 2**)
46. Investigator-sponsored trial: Intravitreal aflibercept injection for the treatment of submacular Vascular pigment epithelial detachment (*the EVEN Study*). Grant from Regeneron: \$313,885.
- Principal Investigators (CK Chan, D Sarraf)
 - Co-investigators (P Abraham, SG Lin, M Lalezary)
 - Independent project approved and **funded by Regeneron**,
 - Nov 2012 onward
47. Investigator-sponsored trial: Evaluation of OCT and visual acuity outcomes after initial loading doses with intravitreal aflibercept injection at 6 months in patients previously treated with ranibizumab or bevacizumab therapy for exudative age-related macular degeneration. Grant from Regeneron: \$48,375. (*The Aflibercept Transition Study*).
- Principal Investigators (A Jain); Co-investigator: (CK Chan)
 - Independent retrospective study approved and **funded by Regeneron**,
 - Nov 2012-Dec 2013.
48. Investigator-sponsored trial: Pharmacokinetic profile of the VEGF inhibitor aflibercept (Eylea[®]) associated with intravitreal injection. Self-funded prospective study.
- Principal Investigator (C Meyer); Co-investigator: (CK Chan)
 - Drug level testing site: University of Bonn, Germany
 - Nov 2012 onward
49. Investigator-sponsored trial: Genetic profiles for eyes with vascularized pigment epithelial detachment.
- Principal Investigator: CK Chan
 - Co-investigators: P Abraham, D Sarraf, P, M Lalezary, SG Lin.
 - Support from Sequenom.
 - Dec 2012-2013.
50. Investigator-sponsored trial: **Genentech's PREVENT Trial: Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Nonexudative AMD Trial (P.R.E.V.E.N.T.)**
- Principal Investigator: M. Lalezary
 - Co-investigators: CK. Chan, SG Lin, P Abraham, D Sarraf, P, M Lalezary, SG Lin. M Wieland, R. Khurana, A Bansel, L Chang, J Palmer, B Lujan, M Jumper, A. Fu, S Haug, R Johnson, R McDonald, P Abraham
 - Reading Center: OCT MD, Inc (B Lujan)
 - Support from Genentech (Budget: \$713,700)
September 2014 onward

INDUSTRY SPONSORED STUDIES & OTHERS

51. FDA Phase III Open Label Prospective Study of the Safety and Efficacy of *Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients with Cytomegalovirus (CMV) Retinitis*, **ISIS Pharmaceutical**, Carlsbad, CA
 - Principal Investigator
 - 1999
52. *Natural history study of unilateral impending macular holes*, prospective study
 - Principal Investigator (self funding)
 - 1995 – 2000.
53. FDA Phase III Multicenter Double Mask Safety and Efficacy *Prospective Study of Vitrase (Hyaluronidase) for Ophthalmic Intra-vitreous injection for Clearance of Severe vitreous Hemorrhage*. Advanced Corneal Systems (ISTA), Irvine, CA
 - Principal Investigator
 - 1999-2001
54. FDA Phase III Multicenter Double Mask Placebo Prospective Control Study on *Photodynamic Therapy with TIN Ethyl Etiopurpurin for Neovascular Age-Related Macular Degeneration*, Miravant, Santa Barbara, CA, Pharmacia
 - Principal Investigator
 - 2000 to 2002.
55. *Novartis Patient Registry for Visudyne® Therapy (Retrospective Study)*; funding by **Novartis Pharmaceuticals**.
 - Principal Investigator
 - 2003 to Dec 2004
56. *Novartis Patient Registry for Visudyne® Therapy (Prospective Study)*, funding by **Novartis Pharmaceuticals**.
 - Principal Investigator
 - 2003 to Dec 2004
57. *Prospective Study of Phosphokinase C beta (PKC β) inhibitor for Diabetic Macular Edema (B7A-MC-MBDL for Reduction in the Occurrence of Center-Threatening Diabetic Macular Edema)*, **Eli Lilly and Company**
 - Principal Investigator
 - Jan 2004 to 2009.
58. *Efficacy of Macugen™ in combination with Visudyne™*, EOP 1012, **Eyetech (OSI Pharmaceuticals)**
 - Principal Investigator

- Nov 2005 to Apr 2007
59. ***Squalamine for neovascular AMD, Genaera MSI 1256 F-301 Trial***, multicenter phase III trial for neovascular AMD, **Genaera Inc.**
- Principal Investigator
 - Oct 2005 to 2006 - sponsor closed study.
60. ***Regeneron’s Clinical Evaluation of Anti-angiogenesis in the Retina Intravitreal Trial AMD-2 (CLEAR-IT AMD-2 (VGFT-OD-0508))***, safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap in patients with neovascular age-related macular regeneration; trial sponsor, **Regeneron Pharmaceuticals, Inc.**,
- Principal Investigator
 - Feb 2006 to Aug 2008
61. ***Posurdex for neovascular AMD***, Multicenter prospective study, **Allergan Inc.**
- Co-Investigator
 - 2006– sponsor closed study
62. ***Novartis Insight CNV Registry***, to capture real-world patient demographics and treatment outcomes in patients with CNV due to AMD.
- Principal Investigator
63. **Principal Investigator, *Fluocinolone Acetonide Intravitreal Inserts***, safety and efficacy of ASI-001A 0.5µg/day and ASI-001B 0.2µg/day Fluocinolone Acetonide Intravitreal Inserts to sham injection in subjects with diabetic macular edema; **Alimera Sciences, Inc.**
- Principal Investigator
 - Mar 2006-2011.
64. ***Allergan’s SIRIUS Study: Safety and efficacy of multiple intravitreal injections of AG 211745 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, Protocol number: 211745-001-00; trial sponsor: Allergan***
- Principal Investigator
 - Oct 2006-2009.
 -
65. ***Genentech’s BRAVO Study for retinal venous occlusion (RVO): efficacy and safety of Ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion*** (Protocol Number: FVF4165g; IND number: BB-IND-8633).
- Principal Investigator
 - Aug 2007-2010.
66. **Principal investigator, *Genentech’s CRUISE Study for retinal venous occlusion (RVO): efficacy and safety of Ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion*** (Protocol #: FVF4166g; IND #: BB-IND-8633).
- Principal Investigator

- Aug 2007-2010.
67. **Genentech's RIDE study for diabetic macular edema (DME): efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with secondary involvement to diabetes mellitus** (Protocol #: FVF4168g; IND #: BB-IND-8633).
- Principal Investigator
 - Aug 2007-2011.
68. **Regeneron's VGFT-OD-0702 (Extension study for VGFT-OD-0508): A Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration**
- Principal Investigator
 - Oct 2007 to present.
69. **Regeneron's View 1: VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration**
- Principal Investigator
 - Aug 2007 to present.
70. **A randomized Placebo controlled double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion;** supported by Thrombogenics Inc.; Chiltern Inc (CRO), Duke University (OCT Reading Center).
- Principal Investigator
 - Feb 2009 till 2012.
71. **Genentech's HARBOR Study**, A Phase III, multicenter, randomized, double-masked study comparing the efficacy and safety of 0.5-mg and 2.0-mg ranibizumab administered monthly or on as needed basis, in patients with subfoveal neovascular age-related macular degeneration (Protocol #: FVF4579g; IND#: NCT00891735).
- Principal Investigator
 - Dec 2010-2012.
72. **Regeneron's VGFT-OD-1009 (VISTA):** A double-masked, randomized, active-controlled, Phase III Study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema.
- Principal Investigator
 - Aug 2011-2014.
73. **Regeneron's VGFTe-RVO-1027 (VIBRANT):** A double-masked, randomized, active-controlled study of the efficacy, safety, and tolerability of intravitreal administration of VEGF Trap-Eye (aflibercept injections [IAI]) in patients with macular edema secondary to branch retinal vein occlusion.
- Principal Investigator
 - April 2012-2014.

74. ***Regeneron's VGFTE-AMD-1124 (RE-VIEW)***: A phase IV, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years, and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.
- Principal Investigator
 - Nov 2012-Mar 2015.
75. ***Acucela 4429-202 Study***: Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (SEATTLE Clinical Trial) (A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration)
- Principal Investigator
 - May 2013 onward.
76. ***Pfizer study***: A Phase 2, randomized, double-masked, placebo-controlled, parallel group, multicenter study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist (PF-04634817) with that of Ranibizumab in adult subjects with diabetic macular edema.
- Principal Investigator
 - May 2014 onward.
77. ***ThromboGenics ORBIT Study***: A multicenter, prospective, observational study will assess clinical outcomes and safety of JETREA® for the treatment of symptomatic vitreomacular adhesion (VMA) as per standard of care in US retina clinics.
- Principal Investigator
 - May 2014 onward.
78. ***Ophthotech SOLARIS***: A Phase III randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of **FOVISTA™** (ANTI-PDGF B pegylated aptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration. June 2014 onward
- Principal Investigator
 - June 2014 onward.
79. ***Genentech's lampalizumab study (GX29176)***: A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration.
- Principal Investigator

- August 2014 onward.
 -
80. ***Allergan’s Protocol 150998-006 "Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration.***
A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Abicipar Pegol administered intravitreally to patients with exudative age-related macular degeneration.
- Principal Investigator
 - January 2016 onward.
81. ***Regeneron’s NCT02712008 (RUBY): Anti-vascular Endothelial Growth factor plus Anti-angiopoietin 2 in Fixed combination therapy Evaluation for the Treatment of Diabetic Macular Edema.***
A randomized, double-masked, active-controlled, phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in comparison with intravitreal aflibercept (IAI) in patients with diabetic macular edema.
- Principal Investigator
 - April 2016 onward
82. ***Regeneron’s NCT02713204 (ONYX): Anti-angiopoietin 2 Plus Anti-vascular endothelial Growth Factor as a therapy for Neovascular Age Related Macula Degeneration: Evaluation of a fixed combination Intravitreal Injection)***
A randomized, double-masked, active-controlled, phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in comparison with intravitreal aflibercept (IAI) in patients with neovascular age-related macular degeneration.
- Principal Investigator
 - April 2016 onward
83. ***Hoffman-la Roche-Genentech’s RO6867461 (Boulevard) Study: Phase-2 multi-center, multiple-dose, randomized, prospective active comparator-controlled, double-masked three parallel arms, 36-week Trial utilizing novel hybrid anti-VEGF and anti-angiopoietin compound in participants with center-involved diabetic macular edema.***
- Principal Investigator
 - 2016 onward
84. ***Clearside Biomedical, Inc: CLS-TA Triamcinolone Injectable Suspension for treatment of retinal vein occlusion. SAPPHIRE: A randomized, controlled trial to study safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept for CRVO.***
A phase-III randomized masked, controlled trial to study the safety and efficacy of suprachoroidal CS-TA in conjunction with intravitreal aflibercept subjects with retinal vein occlusion.
- Principal Investigator
 - June 2017 onward

85. ***Regenerative Patch Technologies LLC: Human embryonic stem cell-derived RPE patch graft for advanced nonexudative AMD***
A phase I/IIA safety study of subretinal implantation of CPCB-RPE1 (human embryonic stem cell-derived retinal pigment epithelial [RPE] cells seeded on a polymeric substrate in subjects with advanced, dry age-related macular degeneration [AMD])
- Principal Investigator
 - June 2017 onward
86. ***Hoffman-La Roche: A Study to Evaluate the Efficacy and Safety of RO6867461 in Participants With Diabetic Macular Edema (YOSEMITE). a Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema***
- Principal Investigator
 - October 2018 onward
87. ***Chengdu KangHong BioTech co, Ltd: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA). A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration (AMD)***
- Principal Investigator
 - October 2018 onward
88. ***Roche Protocol GR40306 (Tenaya): A Phase III, Multicenter, Randomized, Double-masked, Active Comparator-controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-related Macular Degeneration (TENAYA)***
- Principal Investigator
 - October 2019 onward
89. ***Regeneron VGFTe (HD)-AMD-1905 (CANDELA): A Phase-II randomized single-masked, active-controlled study of the safety, tolerability, and efficacy of repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration (CANDELA)***
- Principal Investigator
 - November 2019 onward
90. ***Amgen ABP 938: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration***
- Principal Investigator
 - November 2020 onward
91. ***Iveric Bio, Inc: A Phase 3 Multicenter, Randomized, Double-masked, Sham-controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura™ (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Protocol No: (SEE2008) (Gather 2).***
- Principal Investigator

- December 2020 onward
92. **Ophthea:** A Phase 3, Multicenter, Double-masked, Randomized **Study** to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD (**SHORE Study**); a 2-year, phase 3, multicenter, randomized, parallel-group, sham-controlled, quadruple-masked **study**. Primary efficacy will be determined in Week 52.
- Principal Investigator
 - December 2022 onward
93. **EyePoint Pharmaceutical:** A Phase 2, Multicenter, Prospective, Double-masked, Parallel **Study** of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative **Diabetic Retinopathy (NPDR) (PAVIA Study)**; a prospective, randomized, double-masked **study** evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to sham.
- Principal Investigator
 - January 2023 to May 2023.
94. **Bayer:** BAY 86-5321 / PXL 22153: A randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion (QUASAR Study).
- Principal Investigator
 - June 2023 onward

PRESENTATIONS:

**American Academy of Ophthalmology (AAO) or Association for Research in Visual Science and Optics (ARVO)

++Retina Society, American Society of Retinal Specialists (ASRS), (formerly the Vitreous Society before 2003), Macula Society or Club Jules Gonin, American Ophthalmological Society

1. ****AAO Paper Presentation: Chan CK, Okun E. *The Question of Ocular Tolerance to Intravitreal Liquid Silicone, A Long Term Analysis*, AAO annual meeting, San Francisco, CA, 1985.**
2. **Paper Presentation: Chan CK, Olk RJ, Arribas NP, Escoffery RF, Grand MG, Schoch LH. *Supplemental Photocoagulation on the Buckle After Scleral Buckling Procedures*, Annual Eye Alumni meeting, Washington University, St. Louis, MO, 1985.**
3. **Paper Presentation: Chan CK, Olk RJ, Arribas NP, Escoffery RF, Grand MG, Schoch LH. *Supplemental Photocoagulation on the Buckle*, West Coast Retina Study Club annual meeting, Hawaii, HI, Jan 1987.**

4. **Course Lecture: Chan CK.** *Current Concepts in Diabetic Retinopathy*, Alumni Postgraduate Convention annual meeting, Loma Linda University, Loma Linda, CA, Mar 9, 1987.
5. **Case Presentation: Chan CK.** *Acute Visual Loss Associated with Vitritis and Neuroretinitis in a Young Patient*, Paul Cibis Club 7th biennial vitreoretinal symposium, Montreal, Canada, Jun 1987.
6. **Paper Presentation: Chan CK.** *Acute Retinal Necrosis*, West Coast Retina Study Club annual meeting, San Francisco, CA, Mar 17, 1988.
7. **++ASRS Paper Presentation: Chan CK, Wessels IF.** *Delayed Subretinal Fluid Absorption After Pneumatic Retinopexy*, Vitreous Society 6th annual meeting, Scottsdale, AZ, Dec 1, 1988.
8. ****AAO Poster Exhibit: Chan CK, Wessels IF.** *Delayed Subretinal Fluid Absorption after Pneumatic Retinopexy*. AAO annual meeting, New Orleans, LA, Oct 1989.
9. **Course Lecture: Chan CK.** *Metastatic Tumors of the Eye*, Doheny Eye Institute Tumor Conference, USC, May 12, 1989.
10. **Guest Lecturer: Chan CK.** *Update on Laser Therapy – Wavelength Consideration*, Fluorescein angiography conference, Riverside Community Hospital, Riverside, CA, Jun 9, 1989.
11. **Paper Presentation: Chan CK.** *A Simple Technique for Management of Dislocated Posterior Chamber Implants*, Western Retina Study Club annual meeting, Seattle, WA, Feb 16, 1991.
12. **Case Presentation: Chan CK.** *An Unusual Case of Central Serous Retinopathy Associated with Subretinal Exudates*. Paul Cibis Club 9th biennial vitreoretinal symposium, Napa, CA, May 19, 1991
13. **Paper Presentation: Chan CK.** *A Simple Technique for Management of Dislocated Posterior Chamber Implants*, Paul Cibis Club 9th biennial vitreoretinal symposium, Napa, CA, May 19, 1991
14. **Guest Lecturer: Chan CK.** *Update on Acquired Maculopathy*, Cahuilla Optometric Society, Beaumont, CA, Jan 16, 1992.
15. **Paper Presentation: Chan CK, Kempin SJ, Noble SK., Palmer GA.** *Results and Complications from the Treatment of Choroidal Neovascular Membrane by Systemic Interferon Alpha 2b (Intron)*, Western Retina Study Club annual meeting, Kauai, HI, Feb 18, 1992.
16. ****ARVO Poster Exhibit: Chan CK, Wessels IF, Schultz GR.** *An Improved Technique for Management of Dislocated Posterior Chamber Implants*, ARVO annual meeting, Sarasota, FL, May 8, 1992.

17. ****ASRS Paper Presentation: Chan CK, Kempin SJ, Noble SK., Palmer GA.** *Alpha Interferon for Treatment of Choroidal Neovascularization*, Vitreous Society 10th annual meeting, Ritz Carleton Hotel, Laguna Niguel, CA, Oct 19, 1992.
18. **Paper Presentation: Chan CK, Kempin SJ, Noble SK.** *Outcome and Morbidity of Alpha Interferon for Treating Choroidal Neovascularization*, Riverside Community Hospital Fluorescein Conference, Riverside, CA, Dec 7, 1992.
19. **Paper Presentation: Chan CK, Kempin SJ, Noble SK., Palmer GA.** *Alpha Interferon for the Treatment of Choroidal Neovascular Membranes*, Frontiers in Ophthalmology, Alumni Postgraduate Convention annual meeting, Loma Linda University, Loma Linda, CA, Feb 7, 1993.
20. **Course lecture: Chan CK.** Lecture on “*Other Macular Diseases*” (*Central Serous Chorioretinopathy, Premacular Fibrosis, Macular Holes*), Loma Linda University, Department of Ophthalmology, Loma Linda, CA, Mar 10, 1993.
21. ****ARVO Poster exhibit: Chan CK, Kempin SJ, Noble SK, Palmer GA.** *The Treatment of Choroidal Neovascular Membranes by Alpha Interferon, a Toxicity Study*, ARVO annual meeting, Sarasota, FL, May 1-6, 1993.
22. ****AAO Paper Presentation: Chan CK.** *Pneumatic Maculopexy as an Alternative to Vitrectomy for Treating Idiopathic Senile Macular Holes: a Pilot Study*, AAO annual meeting, Chicago, IL. Nov 16, 1993.
23. **Paper Presentation: Chan CK.** *Pneumatic Maculopexy as an Alternative to Vitrectomy for Treating Idiopathic Senile Macular Holes: a Pilot Study*, Paul Cibis 10th biennial vitreoretinal symposium, Santa Fe, NM, Jun 10, 1993.
24. ****ASRS Poster Exhibit: Chan CK.** *Pneumatic Maculopexy for Treating Impending and Early Macular Holes*, Vitreous Society 11th annual meeting, St. Thomas, American Virgin Islands, 1993.
25. **Paper Presentation: Chan CK.** *Pneumatic Maculopexy without Vitrectomy for Treating Idiopathic Senile Macular Holes: A Pilot Study*, Western Retina Study Club annual meeting, Phoenix, AZ, Jan 28, 1994.
26. **Guest lecture: Chan CK.** *Peripheral Retinal Lesions*, Cahuilla Optometric Association, Wyndham Hotel, Palm Springs, CA, Feb 20, 1994.
27. ****ARVO Poster Exhibit: Chan CK, Wessels IF, Friedrichsen EJ.** *Induction of Posterior Vitreous Detachment by an Expanding Gas Bubble: Pneumatic Maculopexy*, ARVO annual meeting, Sarasota, FL, May 3, 1994.
28. ****AAO Poster Exhibit: Friedrichsen E, Slater J, Loredó L, Ing J, Blacharski P, Garcia C, Chan CK.** *Proton Beam Irradiation of Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration*, AAO annual meeting, Atlanta, GA, 1995.

29. **Paper Presentation: Chan CK.** *Surgical Management of Dislocated Intraocular Lenses*, Loma Linda University Alumni Postgraduate Convention annual meeting, Loma Linda, CA, Mar 7, 1999.
30. **Paper Presentation: Chan CK.** *Bilateral Neuroretinitis in Pediatric Patients*, Western Retina Study Club annual meeting, Newport Beach, CA, Mar 13, 1999.
31. **++ASRS Paper Presentation: Chan CK.** *Retinal Breaks and Detachment after LASIK and PRK*, Vitreous Society 17th annual meeting, Rome, Italy, 1999.
32. **++ASRS Poster Exhibit: Chan CK, Lin SG.** *Modified Sulcus Fixation Technique for Dislocated PCIOL by Temporary Externalization of Haptics*, Vitreous Society 17th annual meeting, Rome, Italy, 1999.
33. **++ASRS Poster Exhibit (Practice Pearls): Chan CK, Lin SG.** *Bilateral Neuroretinitis in Pediatric Patients*, Vitreous Society 17th annual meeting, Rome, Italy, 1999.
34. **Guest Lecturer: Chan CK.** *Surgical Therapy for Macular Holes*, Cahuilla Optometric Association, Wyndham Hotel, Palm Springs, CA, Feb 24, 2000.
35. **Paper Presentation: Chan CK, Arévalo JF, Akbatur HH, Sengün A, Yoon YH, Lee GJ, Tarasewicz DG, Lin SG.** *Vitreoretinal Complications After LASIK and PRK in 85 eyes*, Western Retina Study Club annual meeting, Stevenson, WA, Feb 26, 2000.
36. **Paper Presentation: Chan CK, Gass JDM, Lin SG.** *Acute Idiopathic Exudative Polymorphous Vitelliform Maculopathy*, Paul Cibis Club 14th biennial vitreoretinal symposium, Napa, CA, Jun 27, 2001.
37. **Paper Presentation: Chan CK.** *Micropulse Subthreshold Diode Laser Therapy*, Paul Cibis Club 14th biennial vitreoretinal symposium, Napa, CA, Jun 28, 2001.
38. **Paper Presentation: Chan CK.** *Laser Chorioretinal Anastomosis for Central Retinal Vein Occlusion (Case Presentation)*, Paul Cibis Club 14th biennial vitreoretinal symposium, Napa, CA, Jun 29, 2001.
39. **Course Lecture: Chan CK.** *Vitreoretinal Update (Photodynamic Therapy and Macular Hole Surgery)*, American Society of Ophthalmic Registered Nurses (ASORN) Regional Meeting, Alcon Surgical Facility, Irvine, CA, Sep 8, 2001.

40. **Paper Presentation: Chan CK**, Gass JDM, Lin SG. *Acute Idiopathic Exudative Polymorphous Vitelliform Maculopathy*, Western Retina Study Club annual meeting, Snoqualmie, WA, Mar 23, 2002.
41. **Paper Presentation: Chan CK**, Gass JDM. *Unusual Tapetoretinal Degeneration*, Resident and Alumni Research Day, Loma Linda University, Department of Ophthalmology, Loma Linda, CA, Apr 28, 2002.
42. ****ASRS Case Presentation (Fluorescein Conference): Chan CK**, Gass JDM, Lin SG. *Acute Idiopathic Exudative Polymorphous Vitelliform Maculopathy*, Retina Congress 2002, Combined meeting of the Retina Society and Vitreous Society, San Francisco, CA, Sep 28, 2002.
43. **Paper Presentation: Chan CK**, Tarasewicz DG, Lin SG. *Characteristics of Retinal lesions Following LASIK for Myopic Eyes with Pre-LASIK Retinal Examination*, Resident and Alumni Research Day, Loma Linda University, Department of Ophthalmology, Loma Linda, CA, May 2, 2003.
44. **Paper Presentation (Fluorescein Conference): Chan CK**. *Favorable Response to Valacyclovir for Monocular Patient with Punctate Inner Choroidopathy Suggestive of Its Relationship to Acute Zonal Occult Outer Retinopathy*, Paul Cibis Club 15th biennial vitreoretinal symposium, Aspen, CO, Jun 25, 2003.
45. **Paper Presentation: Chan CK**, Tarasewicz DG, Lin SG. *Features of Retinal lesions after LASIK for Myopic Eyes with Documented Retinal Examination Before LASIK*, Paul Cibis Club 15th biennial vitreoretinal symposium, Aspen, CO, Jun 26, 2003.
46. **Paper Presentation: Chan CK**, Tarasewicz DG, Lin SG. *Prophylactic Retinal Examination and Treatment Associated with LASIK*, Paul Cibis Club 15th biennial vitreoretinal symposium, Aspen, CO, Jun 26, 2003.
47. ****ASRS Poster Presentation: Chan CK**, Tarasewicz DG, Lin SG. *Subconjunctival Migration of Silicone Oil Through a Baerveldt Pars Plana Implant*, ASRS 21st annual meeting, New York, NY, Aug 17, 2003.
48. ****ASRS Paper Presentation (senior author): Lin SG, Chan CK**, Arévalo JF, Akbatur HH, Sengün A, Yoon YH, Lee GJ, Tarasewicz DG. *The Value of Prophylactic Retinal Examination and Treatment Associated with LASIK*, ASRS 21st annual meeting, New York, NY, Aug 19, 2003.

49. **++ASRS Paper Presentation: Chan CK**, Arévalo JF, Akbatur HH, Sengün A, Yoon YH, Lee GJ, Tarasewicz DG, Lin SG. *Characteristics of Retinal Lesions after LASIK for Eyes with Documented Pre-LASIK Retinal Examination*, ASRS 21st annual meeting, New York, NY, Aug 19, 2003.
50. ****AAO Poster Exhibit, (PO 246): Chan CK**, Tarasewicz DG, Arévalo JF, Lin SG, Akbatur HH, Sengün A, Yoon YH, Lee GJ. *Retinal Examination for LASIK Eyes*, AAO annual meeting, Anaheim, CA, 2003.
51. ****AAO Poster Exhibit, (PO 295): Chan CK**, Tarasewicz DG, Arévalo JF, Lin SG, Akbatur HH, Sengün A, Yoon YH, Lee GJ. *Characteristics of post-LASIK retinal lesions*, AAO annual meeting, Session 2, Anaheim, CA, 2003.
52. **Case Presentation: Chan CK**, Tarasewicz DG, *West Nile Virus Meningoencephalitis and Chorioretinitis*, Western Retina Study Club annual meeting, Whistler, British Columbia, Canada, Feb 13, 2004.
53. **Paper Presentation: Chan CK**, Tarasewicz DG, Arévalo JF, Lin SG. *Retinal Examination and Treatment for LASIK Eyes*, Western Retina Study Club annual meeting, Whistler, British Columbia, Canada, Feb 14, 2004.
54. ****ARVO Poster Presentation: Arévalo JF**, Ruiz-Moreno JM, Mendoza, AJ, Fernández CF, Velez-Vazquez W, Rodriguez FJ, Rodriguez A, Rosales-Meneses JL, Dessouki A, **Chan CK**. *Maculopathies After Laser-assisted in Situ Keratomileusis (LASIK)*, ARVO annual meeting, Fort Lauderdale, FL, Apr 29, 2004.
55. **++ASRS Paper Presentation: Chan CK**, Tarasewicz DG, Lin SG. *Epidemiological Trends and Ocular Findings Associated with West Nile Virus Infections in North America*, ASRS 22nd annual meeting, San Diego, CA, 2004.
56. **++ASRS Poster Presentation: Chan CK**, Hawkins H, Lin SG, Tarasewicz DG, Gates R. *Temporary Haptic Externalization for Repositioning Foldable One-piece Acrylic Implants*, ASRS 22nd annual meeting, San Diego, CA, 2004.
57. **++ASRS Instructor: Chan CK**. *Management of Dislocated Implants*, breakfast with the masters roundtable discussions, ASRS 22nd annual meeting, San Diego, CA, 2004.
58. **++ASRS Paper Presentation: Arévalo JF**, Ruiz-Moreno JM, Mendoza AJ, Fernández CF, Velez-Vazquez WM, Rodriguez FJ, Rodriguez A, Rosales-Meneses JL, Dessouki A, **Chan CK**, Mitra RA. *Maculopathies after Laser-assisted in Situ Keratomileusis (LASIK)*, ASRS 22nd annual meeting, San Diego, CA, 2004.

59. **++Retina Society Poster Presentation: Chan CK**, Hawkins H, Lin SG, Tarasewicz DG. *Methods for Repositioning Dislocated Soft Acrylic Posterior Chamber Implants by Temporary Haptic Externalization*, The Retina Society 37th annual scientific meeting, Baltimore, MD, 2004.
60. **++Retina Society Paper Presentation: Arévalo JF**, Mendoza AJ, Fernández CF, Rodríguez FJ, Rodríguez A, **Chan CK**, Dessouki A, Mitra R. *Characteristics and Surgical Outcomes of Full-thickness Macular Hole (MH) After Laser-assisted in Situ Keratomileusis (LASIK)*, The Retina Society 37th annual scientific meeting, Baltimore, MD, 2004.
61. ****AAO Poster Exhibit (PO 370): Arévalo JF**, Mendoza AJ, Fernández CF, Rodríguez FJ, Rodríguez A, Rosales Meneses JL, Dessouki A, **Chan CK**, Mitra R., Ramsay RC. *Characteristics and Surgical Outcomes of Full-thickness Macular Hole After LASIK*. Combined Meeting of AAO and European Society of Ophthalmology annual meeting, New Orleans, LA, 2004.
62. **Case Presentation: Chan CK**, Lin SG, Tarasewicz DG. *Posterior Retinal Granuloma Associated with Trench Fever*. Western Retina Study Club Annual Meeting, Phoenix, AZ, 2005.
63. **Paper Presentation: Chan CK**, Lin SG, Tarasewicz DG. *Choroidal Neovascular Membrane in Cytomegalovirus Retinitis*. Western Retina Study Club Annual Meeting, Phoenix, AZ, 2005.
64. **++ASRS Case Presentation (Fluorescein Conference): Chan CK**, Lin SG. *Unilateral Macular Granulomatous Lesion of Unknown Etiology*. ASRS 23rd annual meeting, Montreal, Canada, 2005.
65. **++ASRS Instructor (Moderator): Chan CK**. *Management of Dislocated Implants*, breakfast with the masters roundtable discussions, ASRS 23rd annual meeting, Montreal, Canada, 2005.
66. **++ASRS Poster Exhibit: Chan CK**, Lin SG. *Favorable Response with Visudyne Photodynamic Therapy for Subfoveal Choroidal Neovascularization due to CMV Retinitis Associated with AIDS*. ASRS 23rd annual meeting, Montreal, Canada, 2005.
67. **++Retina Society Case Presentation (Fluorescein Conference): Chan CK**, Lin SG. *Idiopathic Retinal Granulomatous Lesion*. The Retina Society 38th annual scientific meeting, San Diego, CA, 2005.

68. ****Retina Society Poster Exhibit: Chan CK**, Lin SG. *Positive Response to Visudyne Photodynamic Therapy for Subfoveal Choroidal Neovascularization Associated with CMV Retinitis*. The Retina Society 38th annual scientific meeting, San Diego, CA, 2005.
69. ****AAO Instructional Course 390 (Senior Course Instructor): Chan CK**, Agarwal A, Kokame GT, Gross JG, Ma PE. *Management of Dislocated Lens Fragments, IOL, and Endocapsular Rings: Comprehensive Review, Pearls, and Controversies*. AAO annual meeting, Chicago, IL, 2005.
70. ****AAO Paper Presentation (PA063): Chan CK**, Lin SG, Tarasewicz DG. *Novel Repositioning Technique for Dislocated One-piece All Acrylic Posterior Chamber Implants*. AAO annual meeting, Chicago, IL, 2005.
71. ****AAO Poster Presentation (PO454): Chan CK**, Limstrom SA, Tarasewicz DG, Lin SG. *Ocular Features and Epidemiological Trends of West Nile Virus Infections in North America*. AAO annual meeting, Chicago, IL, 2005.
72. ****ASRS Poster Exhibit: Chan CK**, Meyer CH, Gross JG, Abraham P, Nuthi ASD, Kokame GT, Lin SG. *Retinal Pigment Epithelial Tears after Intraocular Bevacizumab (AvastinTM) Injection for Neovascular Age-related Macular Degeneration*. ASRS 24th annual meeting and European Vitreoretinal Society 6th annual meeting, Cannes, France, 2006.
73. ****Retina Society Paper Presentation: Chan CK**, Gross JG, Meyer CH, Abraham P, Nuthi ASD, Kokame GT, Lin SG. *Retinal Pigment Epithelial Tears Following Intraocular Bevacizumab (AvastinTM) Injection for Neovascular Age-related Macular Degeneration*. Combined meeting of Club Jules Gonin and The Retina Society, Capetown, South Africa, 2006.
74. ****AAO Poster Presentation (PO703): Chan CK**, Gross JG, Meyer CH, Abraham P, Nuthi ASD, Lin SG, Rauser ME. *Retinal Pigment Epithelial Tears Following Intraocular Bevacizumab (Avastin) Injection for Neovascular AMD*. AAO and the Asia Pacific Academy of Ophthalmology annual meeting, Las Vegas, NV, 2006.
75. ****AAO Instructional Course 742 (Senior Course Instructor): Chan CK**, Chang DF, Agarwal Amar, Kokame GT, Ma PE. *Management of Dislocated Lens Fragments, IOLs, and Placement of Capsular Tension Rings: Comprehensive Review, Controversies, and Pearls*. AAO and the Asia Pacific Academy of Ophthalmology annual meeting, Las Vegas, NV, 2006.
76. **Lecture and Instructional course (Loma Linda University Alumni Postgraduate Convention 2007): Chan, CK**. *Corticosteroid Therapy for Retinal Diseases*. Loma Linda University Annual APC, Wong Kerlee Conference Center, Loma Linda, CA, Mar 4, 2007.

77. ****Retina Society Poster Presentation: Chan CK, Lin SG.** *Case Series for Successful Management of Dislocated One-piece All Acrylic Posterior Chamber Implants with Long-Term Follow-up.* Retina Society, Boston, MA, 2007.
78. ****Retina Society Case Presentation (Fluorescein Conference): Chan CK.** *Multiple Branch Retinal Arterial Occlusions in a Patient with SUSAC Syndrome.* Retina Society, Boston, MA, 2007.
79. ****AAO Poster Presentation (PO021): Chan CK, Lin SG.** *Case Series on Successful Repositioning of Dislocated One-piece AcrySof Posterior Chamber Implants with Long-term Follow-up.* American Academy of Ophthalmology annual meeting, New Orleans, LA, 2007.
80. ****AAO Instructional Course 592 (Senior Course Instructor): Chan CK, Chang DF, Agarwal Amar, Kokame GT.** *Management of Dislocated Lens Fragments, IOLs, and Placement of Capsular Tension Rings: Comprehensive Review, Controversies, and Pearls.* AAO annual meeting, New Orleans, LA, 2007.
81. ****ASRS Case Presentation (Fluorescein conference): Chan CK.** *Bilateral Multiple Retinal Arterial Occlusions in a Patient with SUSAC Syndrome.* ASRS, Indian Wells, CA, 2007.
82. ****ASRS Paper Presentation: Chan CK, Lin SG.** *Case Series for Management of Dislocated All Acrylic (One-Piece AcrySof) Posterior Chamber Implants with Long-term Follow-up.* ASRS, Indian Wells, CA, 2007.
83. ****ASRS Symposium moderator: Chan CK (Moderator), Thompson JT (Presiding officer).** *Symposium 7: Instrumentation and Devices/ Hereditary Retinal Disease and Genetics/Ocular Oncology/Socioeconomics.* ASRS, Indian Wells, CA, 2007.
84. ****ASRS Moderator: Chan CK.** *Management of Dislocated Implants, breakfast with the masters roundtable discussions,* ASRS, Indian Wells, CA, 2007.
85. **Case Presentation (Grand round with Professor Alan Bird): Chan CK, Lin SG.** *Acute Exudative Polymorphous Vitelliform Maculopathy Syndrome.* Loma Linda University Ophthalmology Grand Rounds, San Bernardino, CA, May 22, 2008.
86. ****Retina Society Paper Presentation: Chan CK, Meyer CH, Abraham P, Kaiser PH, Gross JG, Kokame GT, Nuthi ASD, Lin SG.** *OCT-measured RPE Height and Volume Index Are Reliable Predictors for Retinal Pigment Epithelial Tears Associated with Intravitreal Bevacizumab Injections for Eyes with Vascularized PED.* Retina Society, Scottsdale, AZ, 2008.
87. **Paper presentation: Chan CK.** *Polymorphous Maculopathy Syndrome.* The Retina Center at Pali Momi, “Celebrating 15 years”, Oahu, HI, Oct 10, 2008.
88. ****ASRS Paper Presentation: Chan CK, Lin SG.** *OCT-measured PED Height and Volume Index are Reliable Predictors for RPE Tears Associated with Intravitreal Bevacizumab (Avastin) Injections.* ASRS, Maui, HI, 2008.

89. ****ASRS Panel member** (Moderator: Kirk Packo; panelists: Albert J Augustin, K. Bailey Freund, **Clement K. Chan**, Susan B. Bressler, Jeffrey S. Heier): *Panel Discussion on Age-related Macular Degeneration*. ASRS, Maui, HI, 2008.
90. ****ASRS Moderator (instructor): Chan CK**. *Management of Dislocated Implants*, breakfast with the masters roundtable discussions, ASRS, Maui, HI, 2008.
91. ****AAO Instructional Course 202 (Senior Course Instructor): Chan CK**, Chang DF, Agarwal Amar, Kokame GT. *Management of Dislocated Lens Fragments, IOLs, and Placement of Capsular Tension Rings: Comprehensive Review, Controversies, and Pearls*. AAO annual meeting, Atlanta, GA, 2008.
92. ****AAO Poster Presentation (PO249): Chan CK**, Meyer CH, Abraham P, Gross JG, Kaiser PH, Kokame GT, Nuthi ASD, Lin SG. *OCT-measured Pigment Epithelial Detachment Height and Volume Index are Reliable Predictors for RPE Associated with Intravitreal Bevacizumab (Avastin) Injections*. AAO annual meeting, Atlanta, GA, 2008.
93. **Paper Presentation: Chan CK**. *Retinal Pigment Epithelial Tears Related to Anti-VEGF Therapy*, Resident Research Symposium, Loma Linda University Department of Ophthalmology, Loma Linda, CA, May 22, 2009.
94. **Paper Presentation: Presenter: Chan CK. Authors:** Scott IU, Van Veldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, and SCORE Study Investigator Group. *Standard Care versus Corticosteroid for Retinal Vein Occlusion Study (SCORE: Baseline Associations Between Retinal Thickness and Visual Acuities for Patients with CRVO and BRVO*. Resident Research Symposium, Loma Linda University Department of Ophthalmology, Loma Linda, CA, May 22, 2009.
95. **Pre-AAO Gass Society Paper Presentation: Chan CK**. *Acute Idiopathic Exudative Polymorphous Vitelliform Maculopathy Syndrome, A Tribute to JDM Gass*. 2nd Annual Gass Society Meeting, Palace Hotel, San Francisco, CA, Oct 22, 2009.
96. ****AAO Retina Subspecialty Day Paper Presentation:** Ip MS, Blodi BA, Scott IU, Van Veldhuisen PC, Oden NL, **Chan CK**, Singerman LJ, Gonzalez V, and the SCORE Study Research Group. *The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study (Report # X): A Randomized Trial to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Vision Loss Associated with Macular Edema Secondary to Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion. The SCORE-CRVO Trial*, San Francisco, CA, Oct 24, 2009.
97. ****AAO Retina Subspecialty Day Paper Presentation (2009):** Scott IU, Blodi BA, Ip MS, Van Veldhuisen PC, Oden NL, **Chan CK**, Tolentino MS, and the SCORE Study Research Group. *The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report X: A Randomized Trial to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Vision Loss Associated with Macular Edema Secondary to Central Retinal Vein Occlusion and*

- Branch Retinal Vein Occlusion. The SCORE-BRVO Trial*, San Francisco, CA, Oct 24, 2009.
98. ****ARVO Poster Presentation: Chan CK**, Abraham P, Nuthi ASD, Chan KM, Lin SG. *Intravitreal Ranibizumab for Treatment of Vascularized Pigment Epithelial Detachment (vPED) Associated with Age-Related Macular Degeneration (AMD): a Prospective Pilot Study*, Broward County Convention Center, Greater Fort Lauderdale, FL, May 2, 2010.
 99. ****ASRS Poster Presentation: Chan CK**, Abraham P, Nuthi ASD, Chan KM, Lin SG. *A Prospective Study of Intravitreal Ranibizumab for Treating Vascularized Pigment Epithelial Detachment due to Age-related Macular Degeneration*. 28th ASRS annual meeting, 2010, Vancouver, British Columbia, Canada, Vancouver Convention Center, Aug 28-Sept 1, 2010.
 100. ****Retina Society Case Presentation: Chan CK**, Abraham P. *High-dose (2.0 mg) ranibizumab treatment for vascularized PED due to AMD*. Retina Society 43rd annual meeting, San Francisco, CA, Sept 23, 2010.
 101. **** Retina Society Paper Presentation: Chan CK**, Abraham P, Nuthi ASD, Chan KM, Lin SG. *Ranibizumab for Treating Vascularized Pigment Epithelial Detachment Due to Age-related Macular Degeneration: A Prospective Randomized study*. Retina Society 43rd annual meeting, San Francisco, CA, Sept 25, 2010.
 102. **Pre-AAO Gass Society Case Presentation: Chan CK**, Abraham P. *Treatment of vascularized retinal pigment epithelial detachment with high-dose ranibizumab*. Third Annual Gass Society Meeting, Hotel Sax, Chicago, IL, Oct 14, 2010.
 103. ****AAO Retina Subspecialty Day Paper Presentation (2010), (Retina 2010: A Panretinal Perspective): Chan CK**, Ip MS, Van Veldhuisen PC, Oden NL, Scott IU, Blodi BA, Tolentino M, and the SCORE Study Investigator Group. *Three-year Cumulative Risk of Neovascularization in the SCORE Study*, McCormick's Place, Chicago, ILL, 1:55 PM-2:02 PM, Oct 16, 2010.
 104. ****Club Jules Gonin Case Presentation (FA conference): Chan CK**. *Management of Idiopathic Retinitis, Vasculitis, Aneurysms, and Neuroretinitis (IRVAN)*. CJG annual meeting, Westin Miyako Hotel, Kyoto, Japan, Nov 03, 2010
 105. ****Club Jules Gonin Paper Presentation: Chan CK**, Ip MS, Van Veldhuisen PC, Oden NL, Scott IU, Blodi BA, Tolentino M, and the SCORE Study Investigator Group. *Incidence of Neovascular Events in Eyes with Macular Edema Secondary to CRVO and BRVO in the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study*. CJG annual meeting, Westin Miyako Hotel, Kyoto, Japan, Nov 05, 2010.
 106. **** ARVO Paper Presentation: Chan CK**, Abraham P, Sarraf D, Nuthi ASD, Lin SG, McCannel CA, Theodore S. *High versus Conventional-dose Ranibizumab for Treating Vascularized Pigment Epithelial Detachments Associated with Age-related Macular Degeneration*. AMD Clinical Trials II, Grand H, Broward County Convention Center, Greater Fort Lauderdale, FL, May 2, 2011.

107. ****ASRS Paper Presentation: Chan CK**, Sarraf D, Abraham P, Nuthi ASD, Lin SG, McCannel CA. *Management of Vascularized Pigment Epithelial Detachments due to AMD with High (2.0MG) vs. Conventional-dose (0.5 MG) Ranibizumab*, 29th ASRS annual meeting, Sheraton Boston Hotel and Shynes Convention Center, Boston, MA, Monday, Aug 22, 2011, 3:21 - 3:29 PM.
108. ****ASRS Poster Presentation:** Sarraf D, Chan CK, Abraham P, Nuthi ASD, Lin SG, McCannel C. *Prospective Analysis of the Incidence and Risk Factors of RPE Tears in Eyes with Fibrovascular Pigment Epithelial Detachment and AMD*, 29th ASRS annual meeting, Sheraton Boston Hotel and Shynes Convention Center, Boston, MA, Monday, Aug 22, 2011, 3:21 - 3:29 PM.
109. ****ASRS Poster Presentation:** Prall FR, Yoon NK, Carlson J, **Chan CK**, Monshizadeh R, Pesavento R, Schneider M, Fan, J. *Retrospective Review of Proton Beam Therapy for Ocular Melanoma*, 29th ASRS annual meeting, Sheraton Boston Hotel and Shynes Convention Center, Boston, MA, Aug 22, 2011.
110. ****ASRS Case Presentation: Chan CK.** *Unusual Choroiditis in a 37-year-old Woman*, Course: Moxie with the Masters. 29th ASRS annual meeting, Sheraton Boston Hotel and Shynes Convention Center, Boston, MA, Aug 23, 2011.
111. **** Retina Society Paper Presentation: Chan CK**, Abraham P, Sarraf D, Nuthi ASD, Lin SG., McCannel CA. *High (2.0 MG) versus Conventional-dose (0.5 MG) Ranibizumab for Managing Vascularized Pigment Epithelial Detachments Associated with Age-related Macular Degeneration*. Retina Society 44th annual meeting, Rome, Italy, Sept 22, 2011.
112. ****AAO Retina Subspecialty Day Paper Presentation (2011), (Retina 2011: The Magical World of Retina): Chan CK**, Abraham P, Sarraf D, Nuthi ASD, Lin SG., McCannel CA. *High-dose (2.0 mg) versus 0.5 mg Ranibizumab for Treating Vascularized Pigment Epithelial Detachment in AMD*. Late Breaking Developments, Valencia Room, Orange County Conventional Center, Orlando, FL, Oct 21, 2011, 01:00 – 01:07 PM.
113. ****AAO Poster Presentation (2011), Chan CK**, Sarraf D, Abraham P, Nuthi ASD, Lin SG., Theodore S, McCannel CA. *2.0 MG vs. 0.5 MG Ranibizumab for Managing Vascularized Pigment Epithelial Detachment in AMD*. 2011 AAO annual meeting, Session 2, Orange County Conventional Center, Orlando, Florida, Oct 24, 25.
114. **** AAO Paper Presentation (2011), Chan CK**, Sarraf D, Abraham P, Nuthi ASD, Lin SG. *Management of Vascularized Pigment Epithelial Detachments Due to AMD with High (2.0 MG) vs. Conventional-dose (0.5 MG) Ranibizumab*. Symposium: Best of the Posterior Segment Specialty Meetings. Room W311. 2011 AAO annual meeting, Orlando, Florida, Oct 25, 12:15 – 1:30 PM.
115. **** ARVO Poster Presentation: Chan CK**, Sarraf D, Abraham P, Nuthi ASD, Lin SG, McCannel CA. *Comparing Outcomes of 0.5 vs. 2.0 mg Ranibizumab Treatment in Eyes*

with Vascularized Pigment Epithelial Detachment based on Lesion Subtypes (Serous Vascularized Pigment Epithelial Detachment versus Fibrovascular Pigment Epithelial Detachment) Associated with AMD, AMD Clinical Research VI, D1202, Hall B/C, Broward County Convention Center, Greater Fort Lauderdale, FL, Wednesday May 9, 2012, 1:45 PM - 3:30 PM.

116. **++ Macula Society 35th Annual Meeting: Chan CK**, Sarraf D, Abraham P, Nuthi ASD, Lin SG, McCannel CA. *Comparison of Outcomes by Lesion Subtypes (Serous Vascularized Pigment Epithelial Detachment versus Fibrovascular Pigment Epithelial Detachment) for 0.5 versus 2.0 mg Ranibizumab Treatment in Eyes with Vascularized Pigment Epithelial Detachment due to AMD*, The David Citadel Hotel, Jerusalem, Israel, June 12, 2012, 10:48-10:57 AM.
117. **++Club Jules Gonin Paper Presentation: Chan, CK** for the Diabetic Retinopathy Clinical Research Network. Authors: Bressler SB, Qin H, Melia M, Bressler NM, Chan CK, Grover S, Miller DG, Stone T. *Worsening of Diabetic Retinopathy in a Randomized Clinical Trial Evaluating Ranibizumab and Triamcinolone: an exploratory Analysis XXVIIIth Club Jules Gonin Biennial Meeting*, Harpa Concert and Conference Centre, Reykjavik, Iceland, June 22, 2012.
118. **++ASRS Paper Presentation: Chan CK**, Abraham P, Sarraf D, Nuthi ASD, Lin SG², McCannel CA, *Vascularized Pigment Epithelial Detachment Treated with 0.5 vs. 2.0 mg Ranibizumab: Analysis of Results Based on Lesion Subtypes*, 30th anniversary and annual meeting of the American Society of Retina Specialists, Aria Resort, Las Vegas, Nevada, August 29, 2012, 9:30-9:34 AM.
119. **++Retina Society Paper Presentation: Sarraf D, Chan CK**, Abraham P, Nuthi ASD, Lin SG, McCannel CA, *Vascularized Pigment Epithelial Detachment Treated with 0.5 vs. 2.0 mg Ranibizumab: Analysis of Results Based on Lesion Subtype and Anatomical Outcome*, 45th annual meeting of the Retina Society, Mandarin Oriental Hotel, Washington DC, Oct 07, 2012.
120. **Pre-AAO Gass Society Paper Presentation: Chan CK.** *Non-enzymatic Relief of Vitreoretinal Adhesion & Traction by Gas Injection in the Era of Pharmacologic Vitreolysis*
Fourth Annual Gass Society Meeting, Mile North Hotel, Chicago, IL, Nov 08, 2012.
121. **Paper presentation (International Retinal Imaging Symposium [IRIS]): Chan, CK.** For the DRCR.net. *Retinal Thickness and Volume Reproducibility Comparison Using Zeiss Stratus Time Domain and Heidelberg Spectralis Spectral Domain OCT in Diabetic Macular Edema*. Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, RPB Auditorium, February 26, 2013.
122. **++ Macula Society 36th Annual Meeting: Chan CK**, Sarraf D, Abraham P, Nguyen DH, Lin SG, Lalezary M, Zhang K. *Analysis of Single Nucleotide Polymorphisms Profile for Eyes with Vascularized Pigment Epithelial Detachment due to AMD*, St. Regis Monarch Beach. Dana Point, CA, February 28, 2013, 08:58-09:06 AM.

123. **** ARVO Poster Presentation: Chan CK**, Sarraf D, Abraham P, Nguyen D, Lalezary M., Lin SG, Zhang K. *Genotype Analysis for Single Nucleotide Polymorphisms Profile of Eyes with Vascularized Pigment Epithelial Detachment due to AMD*, Genetic Risk Factors for Common Eye Disorders with Complex Inheritance; Session 541, Hall C/D, 2013 ARVO Annual Meeting: Life-Changing Research, May 5-9, 2013 in Seattle, Washington. Washington State Convention Center, Seattle, Washington, Thursday, May 9, 2013, 10:30 AM - 1:30 PM.
124. **Named lecture (Loma Linda University 2013 Resident Research Day, Bryce Young Lecture): Chan, CK.** *Results from the Age-Related Eye Disease Study 2*. Loma Linda University Annual Resident Research Day, Wong Kerlee Conference Center, Loma Linda, CA, May 24, 2013.
125. ****ASRS Paper Presentation: Chan CK**, Sarraf D, Abraham P, Nguyen DH, Lin SG, Lalezary M, Zhang K. *Genotype Analysis for Single Nucleotide Polymorphisms Profile of Eyes with Vascularized PED due to AMD vs. Eyes Without AMD and Eyes With Drusen*, 31th anniversary and annual meeting of the American Society of Retina Specialists, Sheraton Centre Toronto, Toronto, Canada, Aug 25, 2013, 11:21-29 AM.
126. ****ASRS Paper-On-Demand (POD) Presentation: Chan CK**, *OCT and Vision Outcomes at Six Months after Transition to Aflibercept for Patients Previously on Ranibizumab or Bevacizumab Therapy for Exudative AMD*, 31th anniversary and annual meeting of the American Society of Retina Specialists, Sheraton Centre Toronto, Toronto, Canada, Aug 24-28, 2013.
127. ****Retina Society Paper Presentation: Chan CK**, Jain A, Sadda S, Varshney N. *Vision and OCT Results at Six Months after Switching to Aflibercept for Patients on Prior Ranibizumab or Bevacizumab Treatment for Exudative AMD*, 46th annual meeting of the Retina Society, The Beverly Hilton Hotel, Beverly Hills, CA, Sept 26-29, 2013.
128. ****AAO Poster Presentation (PO445), Chan CK**, Jain, A, Sadda S, Varshney N, *OCT and Vision results at 6 months after transition to aflibercept for patients on prior ranibizumab or bevacizumab therapy for exudative AMD*. 2013 AAO annual meeting, Session 2, Monday and Tuesday, Morial Conventional Center, New Orleans, LA, Nov 18-19, 2013.
129. **Ophthalmic Imaging Conference (OIC) during AAO 2013. Chan CK**, *Management of anterior dislocation of sustained-release dexamethasone implant (Ozurdex®)* Hilton Riverside, New Orleans, LA, Nov 17, 2013.
130. ****AAO Skill Transfer Course (Diabetes 2013: Workshop on diabetic retinopathy; Course: LAB139A):** Course instructors: Wong KL (chairman), Gottlieb JL, Altaweel MM, Atebara NH, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Drouilhet JH, Johnston RH. 2013 AAO annual meeting, Morial Conventional Center, New Orleans, LA, Rom 343, Nov 19, 2013, 8:00-10:30 A.M.

131. **++ Macula Society 37th Annual Meeting: Chan CK**, Meyer CH, Krohne T, Liu Z. *Pharmacokinetic profile of intravitreal aflibercept in patients receiving intravitreal aflibercept therapy in age-related macular degeneration*, Ocean Reef Club, Key Largo, FL, Feb 20, 2014. 11:24-11:33 AM.
132. **Lecture (Loma Linda University Alumni Postgraduate Convention 2014): Chan CK**. *Results from the Age-Related Eye Disease Study 2, lutein/zeaxanthin and omega-3 fatty acids for age-related macular degeneration and cataract*, National Eye Institute/National Institutes of Health, Centennial Complex, March 9, 2014.
133. **Pacific Retina Club: Chan CK**. *Gas relief of vitreomacular traction in the era of pharmacologic vitreolysis, a case report*, Grand Hyatt, San Francisco, March 28-29, 2014.
134. **** ARVO Poster Presentation: Chan CK**, Jain A, Sadda S, Varshney N. *Results at Six Months after Conversion to Aflibercept for Patients on Prior Ranibizumab or Bevacizumab Treatment for Exudative Age-Related Macular Degeneration*, Session 383, CNV Management, ARVO Annual Meeting: Leading Eye and Vision Research, May 6, 2014, Orlando Convention Center, Orlando, FL, Tuesday, May 6, 2014, 3:45 PM to 5:30 PM.
135. **** ARVO Poster Presentation: Lalezary M, Sarraf D, Abraham P, Lin SG, Chan CK**, *The EVEN Study: An In-depth Prospective Trial on Intravitreal Aflibercept Treatment of Submacular Vascularized Pigment Epithelial Detachment*, Session 383, CNV Management, ARVO Annual Meeting: Leading Eye and Vision Research, May 6, 2014, Orlando Convention Center, Orlando, FL, Tuesday, May 6, 2014, 3:45 PM to 5:30 PM.
136. **** ARVO Poster Presentation: Mein C, Chan CK**, *Pneumatic Maculopexy: A Novel Approach for Treatment of Symptomatic Vitreomacular Traction*, Session 110, Vitreomacular Interface and Management, ARVO Annual Meeting: Leading Eye and Vision Research, May 6, 2014, Orlando Convention Center, Orlando, FL, Sunday, May 4, 2014 from 8:30 AM to 10:15 AM.
137. **++ASRS Paper Presentation: Chan CK**, Meyer CH, Krohne TU, Liu Z. *Intraocular Pharmacokinetic Profile of Aflibercept in Patients Treated with Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration*. 32nd annual meeting of the American Society of Retina Specialists, San Diego, CA, August 11, 2014, 10:51-10:56 AM.
138. **++Club Jules Gonin Case Presentation (FA conference): Chan CK**. *Gas Injection for Vitreomacular Traction in the Era of Pharmacologic Vitreolysis, a Case Report*. CJG annual meeting, Club Jules Gonin biennial meeting, Kongresshaus, Zürich, Switzerland, Wednesday, September 3, 2014.
139. **++Club Jules Gonin Paper Presentation: Meyer CH, Krohne TU, Liu Z, Chan CK**. *Pharmacodynamic and Pharmacokinetic Profile of Intravitreal Aflibercept (Eylea) in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Therapy*. XXIXTH Club Jules Gonin Biennial Meeting, Kongresshaus, Zürich, Switzerland, Age-related Macular Degeneration session, (08:00-9:50 AM), Thursday, September 4, 2014.

140. ****Club Jules Gonin Paper Presentation: Chan, CK** for the Diabetic Retinopathy Clinical Research Network. Authors: *Comparison of Visual and OCT Outcomes in Eyes with and without Prior Vitrectomy Receiving Anti-VEGF Therapy in a Randomized Trial on Ranibizumab Prompt or Deferred Laser for Diabetic Macular Edema*. XXIXTH Club Jules Gonin Biennial Meeting, Kongresshaus, Zürich, Switzerland, Diabetic Retinopathy and Vascular Diseases section, (15:30-17:30 PM), Friday, September 5, 2014.
141. **Pre-AAO Gass Society Paper Presentation: Chan CK, Meyer CH, Krohne TU, Spieker SM, Liu Z.** *Intraocular Pharmacokinetics associated with Aflibercept Injections for Exudative AMD*. Fifth Annual Gass Society Meeting, OMNI Hotel, Picasso Room, Chicago, IL, Oct 16, 2014 (pending).
142. ****AAO Skill Transfer Course (Diabetes 2014: Workshop on diabetic retinopathy; Course: LAB121A):** Course instructors: Wong KL (chairman), Gottlieb JL, Altaweel MM, Atebara NH, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Drouilhet JH, Johnston RH. 2013 AAO annual meeting, McCormick Place, Chicago, IL, Rom N231, Oct 20, 2014, 8:00-10:30 A.M (pending).
143. **Annenberg Center for Health Sciences CME Poster Perspective** (chosen as one of the key posters presented at 2013 American Academy of Ophthalmology Annual Meeting in New Orleans, LA, Nov 16-18, 2013. **Chan CK, Jain, A, Sadda S, Varshney N, OCT and Vision results at 6 months after transition to aflibercept for patients on prior ranibizumab or bevacizumab therapy for exudative AMD.** Discussants, David M. Brown MD, FACS, Allen C. Ho MC, FACS. An audio-based CME activity. Bryn Mawr Communications. September 2014.
144. **** Macula Society 38th Annual Meeting (Case Presentation): Chan CK.** *Pneumatic Vitreolysis and Closure of Macular Hole in the Era of Pharmacologic Vitreolysis*, Montelucia Resort and Spa, Scottsdale, AZ, February 25, 2015, 03-40-03-45 PM.
145. **** Macula Society 38th Annual Meeting (Paper Presentation): Chan CK, Sarraf D, Abraham P, Lalezary M, Lin S.** *Aflibercept Treatment of Pigment Epithelial Detachment in Neovascular AMD. An In-depth Prospective Multimodal Analysis (The Even Study)*. Montelucia Resort and Spa, Scottsdale, AZ, February 28, 2015, 12:16-12:24 PM
146. **Asia-Pacific Academy of Ophthalmology 30th Congress and Chinese Ophthalmological Society 20th Congress** (Invited Speaker for Retina Subspecialty Day, Macula Society Symposium on Diabetic Retinopathy). **Chan CK** on behalf of the diabetic Retinopathy Clinical Research Network. *Comparison of Visual and OCT Outcomes in Eyes with and without Prior Vitrectomy Receiving Anti-Vascular Endothelial Growth Factor Treatment in a Randomized Trial Evaluating Ranibizumab Prompt or Deferred Laser for Diabetic Macular Edema*. Guangzhou Baiyun International Conference Center, Guangzhou, China, March 31, 2015, 09:00-10:30 AM.

147. **Asia-Pacific Academy of Ophthalmology 30th Congress and Chinese Ophthalmological Society 20th Congress** (Invited Faculty for Panel Discussion for Cataract Subspecialty Day). Chair: Chang, DF, Faculty panelists: Yeu, E, Yeoh R, Chang D, Belluci R, Packard R, Vasavada A, Tassignon J, Sun G, and **Chan CK**. *Cataract Complications - Video Cases – You Make the Call (Co-sponsored with ASCRS)*. Guangzhou Baiyun International Conference Center, Guangzhou, China, March 31, 2015, 10:30-12:00 PM.
148. **Asia-Pacific Academy of Ophthalmology 30th Congress and Chinese Ophthalmological Society 20th Congress** (Invited Speaker for Symposium on Diabetic Macular Edema) Co-chairs and moderators: **Chan CK and Friedman SC**. Guangzhou Baiyun International Conference Center, Guangzhou, China, April 3, 2015, 02:30-04:00 PM.
149. **Asia-Pacific Academy of Ophthalmology 30th Congress and Chinese Ophthalmological Society 20th Congress** (Invited Speaker for Symposium on Diabetic Macular Edema) Chan **CK** on behalf of the Diabetic Retinopathy Clinical Research Network. *Five-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for Diabetic Macular Edema*. Guangzhou Baiyun International Conference Center, Guangzhou, China, April 3, 2015, 02:30-04:00 PM.
150. **Asia-Pacific Academy of Ophthalmology 30th Congress and Chinese Ophthalmological Society 20th Congress** (Invited Speaker for Symposium on Age-related Macular Degeneration) Chan **CK**, Sarraf D, Abraham P, Lalezary M, Lin SG. *Aflibercept Treatment of Pigment Epithelial Detachment in Neovascular AMD: An In-depth Prospective Multimodal Analysis (The Even Study)*. Guangzhou Baiyun International Conference Center, Guangzhou, China, April 3, 2015, 04:30-05:00 PM.
151. **Asia-Pacific Academy of Ophthalmology 30th Congress and Chinese Ophthalmological Society 20th Congress** (Invited Speaker for Symposium on Age-related Macular Degeneration) Chan **CK**, Krohne, TU, Spieker S, Liu Z, Meyer CH. *Intraocular Pharmacokinetic Profile of Aflibercept in Patients Treated with Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration*. Guangzhou Baiyun International Conference Center, Guangzhou, China, April 3, 2015, 04:30-05:00 PM.
152. **** ARVO Poster Presentation: Chan, CK, Sarraf D, Abraham P, Lin SG, Lalezary M.** *Prospective Multimodal Analysis of Aflibercept treatment of Pigment Epithelial Detachment in Neovascular AMD: The Even Study*. Session 441. Aflibercept, ARVO Annual Meeting, Colorado Convention Center, Denver, CO, May 6, 2015, 11:00 AM to 12:45 PM.
153. **++ American Ophthalmological Society Poster Presentation: Clement Chan, Atul Jain, Srinivas Sadda, Neeta Varshney.** *OCT and Visual Results at Six Months After Transitioning to Aflibercept for Patients with Prior Ranibizumab or Bevacizumab Treatment for Exudative AMD (An AOS Thesis)*. AOS annual meeting, The Hotel Viking, Newport, RI, May 14-1, 2015.
154. **++ASRS Paper Presentation : Mein CE, Chan CK.** *Pneumatic Vitreolysis for Treatment of Symptomatic Vitreomacular Traction*, 33rd annual meeting of the American Society of Retina Specialists, Vienna, Austria; August 2015.

155. ****Retina Society Paper Presentation: Chan CK**, Sarraf D, Abraham P, Lalezary M, Lin SG. *An In-depth Prospective Multimodal Analysis of Aflibercept Therapy for Pigment Epithelial Detachment in Neovascular AMD*. 48th annual scientific session, Paris, France. Intercontinental Paris, Le Grand Hotel, Oct 11, 2015.
156. **Pre-AAO Gass Society Paper Presentation: Chan CK, Pneumatic Vitreolysis for Treatment of Focal Vitreomacular Traction**. Sixth Annual Gass Society Meeting, George I and II Room, SLS Hotel, 2535 Las Vegas Boulevard, South Las Vegas, NV, Nov 12, 2015.
157. ****AAO Skill Transfer Course (Diabetes 2015: Workshop on diabetic retinopathy; Course: LAB107A)**: Course instructors: Wong KL (chairman), Gottlieb JL, Altaweel MM, Atebara NH, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Drouilhet JH, Johnston RH. 2013 AAO annual meeting, Sands Expo/Venetian Convention Center, Las Vegas, NV, Titian 2203 Room, Nov 15, Sunday, 12:30-2:30 PM, 2015.
158. ****AAO Poster Presentation (PO480), Chan CK**, Sarraf D, Abraham P, Lin SG, Lalezary M, *Even Study: Prospective Multimodal Analysis of Aflibercept for Pigment Epithelial Detachment in Neovascular AMD*. 2015 AAO annual meeting, Session 2, Monday and Tuesday, Hall G, Sands Expo and Conventional Center, Las Vegas, NV, Nov 16-17, 2015.
159. ****Macula Society 39th Annual Meeting (Paper presentation): Chan CK.**, Mein, CE *Pneumatic Vitreolysis for Treatment of Focal Vitreomacular Traction*, Eden Roc Resort, Miami Beach, Fl. February 26, 2016, 11:28-11:36 A.M.
160. **++ American Ophthalmological Society Paper Presentation: Chan CK**, Mein CE. *Management of Focal Vitreoretinal Traction with Pneumatic Vitreolysis*, AOS annual meeting, The Broadmoor Hotel, Colorado Springs, Co., May 22, 2016.
161. ****Club Jules Gonin Paper Presentation: Chan CK**, Mein CE. *Pneumatic Vitreolysis for Treatment of Focal Vitreomacular Traction*. XXXth Meeting of the Club Jules Gonin, Bordeaux, France, July 6-9, 2016.,
162. ****ASRS Paper Presentation (Late Breaker session)**: Chan CK, Mein CE, *Pneumatic Vitreolysis for Effective Treatment of Vitreomacular Traction Syndrome*. The 34th annual meeting of the American Society of Retina Specialists, Marriott Marquis, San Francisco, CA; August 13, 11:45-11:50 A.M., 2016.
163. ****Retina Society Paper Presentation: Chan CK**, Mein CE. *Management of Focal Vitreomacular Traction with Pneumatic Vitreolysis*. The 49th annual scientific session, San Diego, CA, US Grant Hotel, September 2016.
164. ****Retina Society Paper Presentation**: Chen X, Al-Sheikh M, **Chan CK**, Abraham P, Lalezary M, Lin SG, Sadda S, Sarraf D. *Type 1 versus Type3 Neovascularization in PEDs Associated AMD after Anti-VEGF Therapy in the Even Study: Post-hoc Analysis of a*

Prospective Study. The 49th annual scientific session, San Diego, CA, US Grant Hotel, September 2016.

165. **** Pre-AAO Retina Subspecialty Day Paper Presentation: Chan CK, Mein CE.** *Treatment of Vitreomacular Traction with Pneumatic Vitreolysis*. 2016 AAO annual meeting, McCormick Place, North Hall, Chicago, IL, Oct 15, 2016, Saturday, 8:43 AM.
166. **** AAO Poster Presentation (PO225), Chan CK, Mein CE.** *Pneumatic Vitreolysis for Managing Focal Vitreomacular Traction*. 2016 AAO annual meeting, McCormick Place, Chicago, IL, Oct 15, 2016.
167. **** AAO Skill Transfer Course (Diabetes 2016 Lab: Fluorescein Angiography Interpretation; Course: LAB136A):** Course instructors: Wong KL (chairman), Gottlieb JL, Altaweel MM, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Drouilhet JH, Johnston RH. 2016 AAO annual meeting, McCormick Place Convention Center, Chicago, Ill; Room, N231, Nov 17, 2016, Monday, 03:00-5:30 PM.
168. **Asian-Pacific Vitreoretinal Society Paper Presentation: Chan CK.** *Pneumatic Vitreolysis for management of Vitreomacular Traction*. The 10th annual congress, Bangkok, Thailand, December 2016.
169. **Asian-Pacific Vitreoretinal Society Paper Presentation: Chan CK.** *A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (Protocol-T, two-year results)*. The 10th annual congress, Bangkok, Thailand, December 2016.
170. **Asian-Pacific Vitreoretinal Society Paper Presentation: Chan CK.** *Pneumatic Prompt PRP vs Ranibizumab and Deferred PRP for PDR Study (Protocol-S)*. The 10th annual congress, Bangkok, Thailand, December 2016.
171. **** ARVO Poster Presentation (1837 - B0280) (Session 245, Genetics of macular degeneration): Chan, CK, Abraham P, Hafner AD, Perlee, Lorah.** *Frequency of the C3 Gly102 risk variant is higher in AMD patients with Geographic Atrophy compared to patients with Vascular Pigment Epithelial Detachment*. ARVO Annual Meeting, Baltimore Convention Center, Baltimore, MD, May 8, 2017, Monday, 11:00 AM to 12:45 PM.
172. **** ARVO Poster Presentation (3688 - B0313) (Session 383, Age-related macular degeneration: Mein, CE, Chan, CK, Crosson JN: [non-inherited])** *Pneumatic Vitreolysis (PVL) for the Treatment of Vitreomacular Traction Syndrome (VMT)*. ARVO Annual Meeting, Baltimore Convention Center, Baltimore, MD, May 9, 2017, Tuesday, 03:45 PM to 05:00 PM.
173. **** ARVO Poster Presentation (410 - A0276) (132: AMD and anti-VEGF therapy) :** Lalezary M, Elman, M, Lin, SG, Bansal, A, Khurana, R, Wieland, M, Chang, L, Palmer, J, Lujan, B, Abraham, P, **Chan, CK**. Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-Exudative AMD Trial (PREVENT): A prospective controlled clinical trial. ARVO Annual Meeting, Baltimore Convention Center, Baltimore, MD, May 7, 2017, Sunday, 01:30 PM to 03:15 PM.

174. **++ Macula Society 40th Annual Meeting (Paper presentation): Chan CK.,** Mein, CE *Pneumatic Vitreolysis for Managing Symptomatic Vitreomacular Traction*, Shangri-La Hotel, Singapore. June 07, 2017, 05:03-05:12 P.M.
175. **++ American Ophthalmological Society Poster Presentation: Chan CK, Abraham P,** Hafner AD, Perlee, Lorah., *Comparison of Single Nucleotide Polymorphism Profiles Among Different Phenotypes of Neovascular Age-related Macular Degeneration* AOS annual meeting, The Omni Homestead Resort, Hot Springs, VA, May 18-21, 2017.
176. **++ASRS Poster Presentation:** Chan CK, Mein CE, *Single Nucleotide Polymorphism Profiles Associated with Three Common Phenotypes of Advanced Age-related Macular Degeneration*. The 35th annual meeting of the American Society of Retina Specialists, Boston Marriott Copley Place, Boston, MA; August 11-15, 2017.
177. **++ASRS Rapid Fire Paper Presentation:** Mein CE, **Chan CK.** *Pneumatic Vitreolysis for Treatment of Symptomatic Vitreomacular Traction with or Without Stage-2 Macular Hole*. The 35th annual meeting of the American Society of Retina Specialists, Boston Marriott Copley Place, Boston, MA; August 11-15, 2017.
178. **++Retina Society Paper Presentation: Chan CK,** Mein CE. *Management of Focal Vitreomacular Traction with or without Stage-2 Macular Holes with Pneumatic Vitreolysis*. The 50th annual scientific session, Boston, MA, Fairmont Copley Plaza Hotel, October 7, 2017.
179. **Pre-AAO Gass Society Paper Presentation: Chan CK, Abraham P.** *Comparison of Single Nucleotide Polymorphism Profiles Associated with Three Phenotypes of Advanced Age-related Macular Degeneration*. Royal Sonesta Hotel, New Orleans, LA, November 9, 2017.
180. ****AAO Poster Presentation (PO216), Chan CK,** Mein CE. *Vitreomacular Traction with or without Stage-2 Macular Holes Managed with Pneumatic Vitreolysis*. 2017, AAO annual meeting, N. Morial Convention Center, New Orleans, LA, Nov 11,12, 2017.
181. ****AAO Skill Transfer Course (Diabetes 2017 Lab: Fluorescein Angiography Interpretation; Course: LAB136A):** Course instructors: Wong KL (chairman), Abrams G, Altaweel MM, Atebara N, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK,** Chandra S, Drouilhet JH, Ip M, Johnston RH, Kinyoun J, Pauler S, Richter E. 2017 AAO annual meeting, N. Morial Convention Center, New Orleans, Monday, 09:00-11:30 AM..
182. **Asian-Pacific Vitreoretinal Society Paper Presentation: Chan CK. AMD symposium:** *New Drug and Therapeutic Targets for Neovascular Age-related Macular Degeneration*. The 11th annual congress, Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia, December 8, 2017.
183. **Grand Rounds, Department of Ophthalmology, Loma Linda University: Chan CK.** *New Drug and Therapeutic Targets for Exudative Age-related Macular Degeneration*.

Department of Ophthalmology, Loma Linda University, FMO Suite 1800, Loma Linda, CA, 7:00 AM, January 3, 2017.

184. **Doheny Eye Institute-David Geffen School of Medicine (UCLA). Evolving Imaging and Treatment Modalities Conference.** Chan CK. *Pneumatic Vitreolysis, an Emerging Treatment Option for Managing Focal Vitreomacular Traction*, Moseley Salvatori Conference Center, Los Angeles, CA, February 03, 2018.
185. **++ Macula Society 41st Annual Meeting (Paper presentation): Chan CK.,** Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G, Lujan BJ. *Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-exudative AMD Trial (PREVENT): A prospective controlled clinical trial*, Beverly Hilton, Los Angeles, CA, February 23, 2018, 11:28-11:37 A.M.
186. **** ARVO Poster Presentation: Henao M, Mein, CE, Chica MA, Lane RG, Chan, CK, Managing Focal Vitreomacular Traction with Pneumatic Vitreolysis, An Emerging Surgical Technique.** ARVO Annual Meeting, Honolulu Convention Center, Honolulu, HI, May 2018.
187. **++American Ophthalmological Society Presentation: Chan CK.,** Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G, Lujan B. *Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Fellow Eyes with Non-exudative AMD Trial (PREVENT): A Prospective Controlled Clinical Trial.*, The 154th annual meeting of the American Ophthalmological Society, Monarch Beach Resort, Dana Point, CA, May 2018.
188. **++Club Jules Gonin Paper Presentation: Chan CK.,** Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G, Lujan B. *Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Fellow Eyes with Non-exudative AMD Trial (PREVENT): A Prospective Controlled Clinical Trial, Preliminary Results*, Jersey, Channel Islands, July 2018,
189. **++ASRS Presentation : Mein CE, Chan CK.** *Treatment of Focal Vitreomacular Traction with Pneumatic Vitreolysis, An Emerging Surgical Technique.* The 36th annual meeting of the American Society of Retina Specialists, Vancouver, BC, Canada, July 2018.
190. **++ASRS Presentation: Lalezary M, Chan CK.,** Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G, Lujan B. *Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Fellow Eyes with Non-exudative AMD Trial (PREVENT): A Prospective Controlled Clinical Trial.*, The 36th annual meeting of the American Society of Retina Specialists, Vancouver, BC, Canada, July 2018.
191. **++Retina Society Paper Presentation: Chan CK.,** Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G, Lujan B. *Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes with Non-exudative AMD Trial (PREVENT): Interim Report of A Prospective Controlled Clinical Trial.* The 51st annual scientific session, San Francisco, CA, Palace Hotel, September 13, 2018.

192. ****AAO Poster Presentation (PO545), Chan CK, Mein CE.** *Pneumatic Vitreolysis, An Emerging Surgical Procedure for Treatment of Focal Vitreomacular Traction.* 2018, AAO annual meeting, McCormick Place, Chicago, IL., Oct 29,30, 2018.
193. ****AAO Skill Transfer Course (Diabetes 2018 Lab: Fluorescein Angiography Interpretation; Course: LAB129A):** Course instructors: Wong KL (chairman), Abrams G, Altaweel MM, Atebara N, Berrocal MH, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Chandra S, Drouilhet JH, Ip M, Johnston RH, Pauler S. 2018 AAO annual meeting, McCormick Place,N231, Chicago,IL,10/29/2018. 9:00-11:30 A.M.
194. **++ Retina Society Paper Presentation: Chan CK, Mein CE.** Pneumatic Vitreolysis for Resolving Focal Vitreomacular Traction: An Update on Clinical Outcome. 2019 Retina Society, 52nd Scientific Program, Landmark Hotel, London, UK, Thursday, 05:07-05:13 PM, Sept 12, 2019.
195. **Eight Gass Fellowship Society Paper Presentation: Chan CK, Abbassi Sam.** *Mystery Case: Autoimmune Retinopathy and Optic Neuropathy Associated with Enolase Positive Renal Oncocytoma,* Le Meridien Hotel, San Francisco, CA, October 10, 2019.
196. ****AAO Skill Transfer Course (Diabetes 2019 Lab: Fluorescein Angiography Interpretation; Course: LAB 127):** Course instructors: Wong KL (chairman), Abrams G, Altaweel MM, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Chandra S, Drouilhet JH, RH, Pauler S. 2019 AAO annual meeting, Moscone Convention Center South 5, San Francisco, CA, 10/14/2019, 9:00-11:30 A.M.
197. **++ Macula Society 43rd Annual Meeting (Paper presentation): Chan CK., Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Lujan, BJ, Yiu G.** *Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-exudative AMD Trial (PREVENT): A prospective controlled clinical trial (Updated Report).* Rancho Bernardino Inn, Rancho Bernardino, CA, 02/21/2020, 11:59-12:08.
198. **++ Retina Society Paper Presentation: Lalezary M, Abraham P, Chan CK, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G.** *Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-exudative AMD Trial (PREVENT): A prospective controlled clinical trial (Final Report).* 2020 Retina Society VR, 53rd Scientific Program, Virtual Presentation, 09/21/2020 (2020 Retina Society Virtual Meeting).
199. **++Club Jules Gonin Paper Presentation: Chan CK., Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G, Lujan B** *Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Fellow Eyes with Non-exudative AMD Trial (PREVENT): A Prospective Controlled Clinical Trial, Final Results,* 2020 CJG Virtual Meeting, 09/02/2020, 02:20 PM European Central Time.
200. ****AAO Retina Subspecialty Day Paper Presentation (2020), (Retina 2020: Vision for the Future): Chan CK, Lalezary M, Abraham P, Elman M, Lin SG, Khurana R, Bansal A, Wieland M, Palmer J, Yiu G.** *The Prevent Trial.* Virtual annual meeting, (2020 AAO Virtual Meeting, On-Demand).

201. ****AAO Skill Transfer Course (Diabetes 2020 Lab: Fluorescein Angiography Interpretation; Course: LAB 119A) :** Course instructors: Wong KL (chairman), Abrams GW, Altaweel MM, Atebarra NH, Berrocal MH, Braunstein RA, Browning DJ, Brucker AJ, **Chan CK**, Drouilhet JH, Gottlieb J Ip MS, Miller JB, Niffenegger JH, Pautler SE. 2029 AAO annual meeting, Sands/Expo Convention Center, Virtual Annual Meeting (On-Demand).
202. **++ Retina Society Paper Presentation: Chan CK, Mein CK.** *A Randomized Clinical Trial of Pneumatic Vitreolysis for Vitreomacular Traction: DRCR Retina Network Protocol AG.* 2021 Retina Society 54th Scientific Program, Ritz Carleton, Chicago, Chicago, Ill, 9/30/2021, Thursday 8:42 AM.
203. **++ASRS Paper Presentation:** *A Randomized Clinical Trial of Pneumatic Vitreolysis for Vitreomacular Traction: DRCR Retina Network Protocol AG* ASRS 39th Annual Meeting. JW Marriott Hill Country Resort and Spa, San Antonio, Texas. Oct 10, 2021, Sunday, 1:56-2:02 PM Central Daylight Time.
204. ****AAO Skill Transfer Course (Diabetes 2021 LAB 133A): Fluorescein Angiography Interpretation.** Wong KL, Abrams GW, Altaweel MM, Atebara NH, Berrocal MH, Braunstein RA, Browning DJ, Brucker AJ, Chan CK, Chandra SR, Drouilhet JH, Gottlieb J, Ip MS, Johnston RH, Miller JB, Niffenegger JH, Pautler SE. 2021 Annual Meeting, Ernest N. Morial Convention Center, Room 343, New Orleans, 11/14/2021, 2:00 to 4:00 PM.
205. **++ Macula Society 44th Annual Meeting (Paper presentation): Chan CK.,** Beaulieu, WT, Lujan BJ, Yiu, G, *Quantitative Analyses of Geographic Atrophy, Drusen, and Macular Dimensions in the Prophylactic Ranibizumab in Fellow Vulnerable High-Risk Eyes with Nonexudative AMD in Patients with Exudative AMD in One Eye (PREVENT Trial).* Ritz-Carleton Hotel, Potsdamer Platz, Berlin, Germany, Thursday 06/09/2022, 12:39-12:45 PM.
206. **++Club Jules Gonin Paper Presentation: Chan CK.,** Beaulieu, WT, Lujan BJ, Yiu, G, Lalezary M. *Changes in Drusen, Macular Volume, and Geographic Atrophy in the Prophylactic Ranibizumab in Fellow Vulnerable High-Risk Eyes with Nonexudative AMD in Patient with Exudative AMD in One Eye (PREVENT).* Valamar Lacroma Hotel, Dubrovnik, Croatia. Thursday, 09/08/2022, 8:35-8:42 AM.
207. ****AAO Poster Presentation (Abstract ID 30069527) (PO), Chan CK,** Beaulieu, WT, Lujan BJ, Yiu, G, Lalezary M. *Changes in Geographic Atrophy, Drusen, and Macular Thickness after Prophylactic Ranibizumab to Prevent Neovascular AMD in a Randomized Trial.* 2022 AAO annual meeting, McCormick Place, Chicago, IL., Sept 30-Oct 03 (impending).
208. ****AAO Skill Transfer Course (Diabetes 2022 LAB 134A): Fluorescein Angiography Interpretation.** Wong KL, Abrams GW, Altaweel MM, Atebara NH, Berrocal MH, Braunstein RA, Browning DJ, Brucker AJ, Chan CK, Chandra SR, Drouilhet JH, Gottlieb J, Ip MS, Johnston RH, Miller JB, Niffenegger JH, Pautler SE. 2022 Annual Meeting, McCormick Place, Chicago, Ill. N231, 10/02/2022, 2:30 to 4:30 PM.
209. **++ Retina Society Paper Presentation: Chan CK,** Beaulieu, WT, Lujan BJ, Yiu, G, Lalezary M. *Analyses of Geographic Atrophy, Drusen, and Macular Volume in the Prophylactic Ranibizumab in Fellow Vulnerable High-Risk Eyes with Nonexudative Age-related Macular Degeneration in Patients with Exudative AMD in One Eye (PREVENT)*

- Trial*. 2022 Retina Society 55th Scientific Program, Langham Huntington Pasadena, 11/04/2022.
210. **Tenth Gass Fellowship Meeting, Case presentation: Chan CK.** *Two cases, demonstrating the mechanism of pneumatic vitreolysis for releasing vitreomacular traction, and step improving the safety and ease of vitrectomy for repairing a macular hole.* Beacon Grand Hotel, San Francisco, CA Nov 2, 2023.
 211. **First inaugural UVP Presentation Program at the AAO;** Chan, CK. *Update of Retinal Drugs in Ophthalmology.* JW Marriott, Union Square, Nov 4, 2023.
 212. ****AAO Skill Transfer Course (Diabetes 2023 LAB 127A): Fluorescein Angiography Interpretation.** Wong KL, Abrams GW, Altaweel MM, Atebara NH, Berrocal MH, Braunstein RA, Browning DJ, Brucker AJ, Chan CK, Chandra SR, Drouilhet JH, Gottlieb J, Ip MS, Johnston RH, Miller JB, Niffenegger JH, Pautler SE. 2023 Annual Meeting, Moscone South 11, 11:00 A.M. to 1:00 P.M.
 213. **Chan CK,** Lalezary M, Beaulieu, WT, Lujan BJ, Yiu, G. *Efficacy and Safety Results of the PREVENT TRIAL.* Doheny Eye Institute/UCLA, 2nd International Retina Symposium, Doheny Eye Institute Auditorium, Jan 27, 2024.
 214. **++Chan CK,** Henao M. *Cyst Extraordinaire, a case report.* 2024 Macula Society Annual meeting, La Quinta Resort and Club, La Quinta, CA, Jan 7, 2024.
 215. **++Chan CK,** Henao K. *Extraordinary Cyst, a case report.* 2024 Club Jules Gonin Annual meeting, Palma de Mallorca, Spain, May 22, 2024.
 216. **Chan CK.** DRCR Retina Network Clinical Trials, Combined annual meeting of Pacific Retina Club and International Retinal Imaging Symposium, 425 Westwood Plaza, UCLA Meyer & Renee Luskin Conference Center, May 31, 2024.
 217. ****AAO Skill Transfer Course (Diabetes 2024 LAB 115A): Fluorescein Angiography Interpretation.** Wong KL, Abrams GW, Altaweel MM, Atebara NH, Berrocal MH, Braunstein RA, Browning DJ, Brucker AJ, Chan CK, Gottlieb JL Ip, Michael S, Johnston RH, E Uchiyama, N231. McCormick Place, October 19, Saturday, 3:00-5:00 PM, pending.
 218. ****AAO Macula Society Symposium (Pathway to Atrophy in AMD), Panel Discussion, Moderator:** Judy Kim, Panelists: Rick Spaide, Dan Martin, Clement Chan, Glenn Jaffe, David Brown, 2024 AAO Chicago, McCormick Place, October 20, Saturday 8:00-9:30 AM.
 219. **++Chan CK,** Satta S, Lim JL, Wang Y, Hibar D, Maun A, Lu H, Albrecht T, Amador M, Gibson K, Litts, KM. On behalf of the YOSEMITE/RHINE investigators. *Impact of Early Intraretinal Fluid Reduction on Outcomes in DME.* Macula Society Annual meeting, Sunseeker Resort, Charlotte Harbor, FL, Feb 13, 2025 (Pending)
 220. **++ American Ophthalmological Society Presentation:** Chan CK., Lujan B, Beaulieu WT, Yiu G, Lalezary M, Elman M. *Changes in geographic atrophy, drusen, and macular volume and thickness in eyes with intermediate age-related macular degeneration (AMD) in patients with neovascular AMD in their contralateral eyes, the PREVENT Trial.*

The 161st annual meeting of the American Ophthalmological Society, The Rits-Carleton, Naples, FL, May 15-17, 2025 (Pending).

221. **Chan CK, Sadda S, Lim JL, Wang Y, Hibar D, Maun A, Lu H, Albrecht T, Amador M, Gibson K, Litts, KM.** On behalf of the YOSEMITE/RHINE investigators. *Impact of Early Intraretinal Fluid Reduction on Outcomes in DME*. Combined annual meeting of Pacific Retina Club and International Retinal Imaging Symposium, 425 Westwood Plaza, UCLA Meyer & Renee Luskin Conference Center, June 5-7, 2025 (Pending)..

PUBLICATIONS: ** Peer-reviewed publications

1. **Publication: Chan CK, McNeill J.** *Corneal transplantation: current concepts and considerations*. Loma Linda University Surgeons 1982; 01: 11-19.
2. ****Publication: Chan CK, Huffaker G.** *Herpes zoster ophthalmicus and contralateral hemiparesis*. J Clinical Neur Ophthalmol 1983; 03: 111-119. (J Lawton Smith, M.D, Editor-in-Chief.)
3. ****Publication: Chan CK, Okun E.** *The question of ocular tolerance to intravitreal liquid silicone, a long term analysis*. Ophthalmol 198July 6; 93: 651-660.
4. ****Publication: Chan CK, Olk RJ, Arribas NP, Escoffery RF, Grand MG, Schoch LH.** *Supplemental photocoagulation on the buckle for prevention of surgical revision after scleral buckling procedures*. Arch Ophthalmol 1987; 105: 490-496.
5. **Editing of book (text and references):** Charles S. Vitreous Microsurgery, 2nd edition, Kist K, editor, Williams and Wilkins, Baltimore, 1987.
6. ****Publication: Chan CK, Wessels IF.** *Delayed subretinal fluid absorption after pneumatic retinopexy*. Ophthalmol 1989; 96: 1691-1700.
7. **Inclusion of illustration from article:** *Supplemental photocoagulation on the buckle for prevention of surgical revision after scleral buckling procedures*. In: Ophthalmic Surgery Loose Leaf Workbook and Update Service, Lindquist TD, Lindstrom RL, editors, Year Book Medical Publishers, Chicago, 1990.
8. ****Publication: Chan CK, Wessels IF.** *Delayed absorption of subretinal fluid after pneumatic retinopexy [letter]*. Ophthalmol 1990; 97: 695-696.
9. ****Publication: Chan CK, Wessels IF.** *Delayed absorption of subretinal fluid [letter]*. Ophthalmol 1990; 97: 961-962.
10. **Abstract: Chan CK, Wessels IF.** *Delayed fluid absorption after pneumatic retinopexy*. Year Book of Ophthalmol, pp 238-239, Benson W, editor, Wills Eye Hospital, CV Mosby, St. Louis, 1991.
11. ****Publication: Chan CK, Wessels IF.** *Chronic macular detachment following pneumatic retinopexy [Letter]*. Retina 1991; 11: 360.
12. ****Publication: Chan CK.** *An improved technique for management of dislocated posterior chamber implants*. Ophthalmol 1992; 99: 51-57.

13. ****Publication: Chan CK, Reports by the Silicone Study Group.** Arch Ophthalmol 1993; 111: 428-91.
14. ****Publication: Chan CK, Kempin SJ, Noble SK, Palmer GA.** *The treatment of choroidal neovascular membranes by alpha interferon: An efficacy and toxicity study.* Ophthalmol 1994; 101: 289-300.
15. ****Publication: Chan CK, Wessels IF, Friedrichsen EJ.** *Treatment of idiopathic macular holes by induced posterior vitreous detachment.* Ophthalmol 1995;102: 757-767.
16. ****Publication: Schatz H, McDonald HR, Johnson RN, Chan CK, Alexander RI, Berger AR, Folk JC, Robertson DM.** *Subretinal fibrosis in central serous chorioretinopathy.* Ophthalmol 1995; 102: 1077-1085.
17. **Book Chapter: Chan CK, Lin SG.** *Management of dislocated lens and lens fragments by the vitreoretinal approach.* In Agarwal et al, eds. Phacoemulsification, Laser Cataract Surgery and Foldable IOL's, pp 417-423, 2nd edition, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2000 (distributed by Slack Inc. and Highlights of Ophthalmol).
18. **Book Chapter: Chan CK, Schultz GR.** *Management of dislocated implants by the vitreoretinal approach.* In Agarwal et al, eds. Phacoemulsification, Laser Cataract Surgery and Foldable IOL's, pp 424-428, 2nd edition, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2000 (distributed by Slack Inc. and Highlights of Ophthalmol).
19. ****Publication: Chan, CK, Lawrence FC.** *Macular hole after laser in situ keratomileusis and photorefractive keratotomy.* Am J Ophthalmol 2001; 131: 666-667.
20. ****Book Chapter: Chan CK, Agarwal R, Agarwal S, Agarwal AM.** *Management of dislocated intraocular implants.* In P Nagpal, IH Fine, guest eds. Ophthalmology Clinics of North America, Volume 14, No.4, Posterior Segment Complications of Cataract Surgery, pp 681-693, WB Saunders, Philadelphia, December 2001 (*Elsevier Science.*)
21. **Book Chapter: Chan CK, Lin SG.** *Management of dislocated lens and lens fragments by the vitreoretinal approach.* In Agarwal et al, Apple D, Buratto L, Alio J, Pandrey S, eds. Textbook of Ophthalmology, Glaucoma, Lens, Uveal Tract, Ocular Therapeutics, Chapter 216, Volume 3, pp 1950-1955, 1st edition, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2002 (distributed by Slack Inc. and Highlights of Ophthalmol).
22. **Book Chapter: Chan CK, Schultz GR.** *Management of dislocated implants by the vitreoretinal approach.* In Agarwal et al, Apple D, Buratto L, Alio J, Pandrey S, eds. Textbook of Ophthalmology, Glaucoma, Lens, Uveal Tract, Ocular Therapeutics, Chapter 217; pp 1956-1963, 1st edition, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2002 (distributed by Slack Inc. and Highlights of Ophthalmol).
23. **Book Chapter: Chan CK, Lin SG.** *Scleral buckling for the repair of retinal detachment.* In Agarwal et al, Apple D, Buratto L, Alio J, Pandrey S, eds. Textbook of Ophthalmology, Retina and Vitreous, Systemic Diseases, Miscellaneous, Volume 4, Chapter 294, pp 2691-2716, 1st edition, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2002 (distributed by Slack Inc. and Highlights of Ophthalmol).
24. **Book Chapter: Chan CK, Lin SG.** *Complications associated with scleral buckling procedures.* In Agarwal et al, Apple D, Buratto L, Alio J, Pandrey S, eds. Textbook of Ophthalmology, Retina and Vitreous, Systemic Diseases, Miscellaneous, Volume 4, Chapter

- 295, pp 2717-2723, 1st edition, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2002 (distributed by Slack Inc. and Highlights of Ophthalmol).
25. **Book Chapter: Chan CK, Lin SG.** *Management of dislocated lens fragments.* In Agarwal S, Agarwal A, Agarwal A, eds. Phako, Phakonit, and Laser Phako, a Quest for the Best, Section VII. Complications, Chapter 44, pp 471-484, 1st edition, Highlights of Ophthalmol Inc, Columbia, Imprelibros SA, 2002 (distributed by Slack Inc. and Highlights of Ophthalmol).
 26. **Book Chapter: Chan CK, Lin SG.** *Current concepts in managing infectious endophthalmitis: a comprehensive review.* In Agarwal S, Agarwal A, Agarwal A, eds, Boyd S, consultant. Phako, Phakonit, and Laser Phako, a Quest for the Best, Section VII. Complications, Chapter 47, pp 505-534, 1st edition, Highlights of Ophthalmol Inc, Columbia, Imprelibros SA, 2002 (distributed by Slack Inc. and Highlights of Ophthalmol).
 27. **Book Chapter: Agarwal Am, Agarwal S, Agarwal At, Pandey S, Chan CK.** *FAVIT—A technique for removing dropped nucleus during phacoemulsification.* In: Advances in Ophthalmology, Vol 1, Chapter 12, pp 104-108, 1st edition, Garg A, Pandey SK, Sharma V, Apple DJ, editors, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2003.
 28. **Book Chapter: Chan CK, Schultz GR.** *Management of dislocated implants by the vitreoretinal approach.* In: Advances in Ophthalmology, Vol 1, Chapter 12, pp 109-117, 1st edition, Garg A, Pandey SK, Sharma V, Apple DJ, editors, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2003.
 29. ****Publication: Chan CK, Gass JDM, Lin SG.** *Acute exudative polymorphous vitelliform maculopathy syndrome.* Retina 2003; 23: 453-462.
 30. **Publication: Chan CK, Lin SG.** *Retinal lesions and LASIK.*, Ocular Surgery News, 2003; November 15, Vol 21, No. 22, 3,138-139
 31. ****Publication: Chan CK, Agarwal Am, Agarwal At, Agarwal S.** *Surgical management of the malpositioned intraocular implant.* Comp Ophthalmol Update 2004; 5: 103-15.
 32. **Book Chapter: Chan CK, Lin SG.** *Management of dislocated lens and lens fragments by vitreoretinal approach.* In: Clinical Practice in Small Incision Cataract Surgery (Phaco Manual), Chapter 49, pp 524-531, 1st edition, Garg A, Fry LL, Tabin G, Gutiérrez-Carmona FJ, Pandey SK, editors, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2004.
 33. **Book Chapter: Chan CK, Schultz GR.** *Management of dislocated implants by vitreoretinal approach.* In: Clinical Practice in Small Incision Cataract Surgery (Phaco Manual), Chapter 50, pp 532-541, 1st edition, Garg A, Fry LL, Tabin G, Gutiérrez-Carmona FJ, Pandey SK, editors, Jaypee Brothers Medical Publishers (P) Ltd; New Delhi, 2004.
 34. **Publication: Chan CK,** *Retinal complications after LASIK,* Review of Ophthalmol May 2004, 96-98.
 35. ****Publication: Chan CK, Arévalo JF, Akbatur HH, Sengün A, Yoon YH, Lee GJ, Tarasewicz DG, Lin SG.** *Characteristics of sixty myopic eyes with pre-laser in situ keratomileusis retinal examination and post-laser in situ keratomileusis retinal lesions.* Retina 2004; 24:706-713.
 36. **Book Chapter: Chan CK, Lin SG.** *Management of dislocated lens and lens fragments by the vitreoretinal approach.* In: Phacoemulsification, Volume 2, Chapter 74, pp 781-788, 3rd edition, Agarwal S, Agarwal At, Agarwal Am, Fine IH, Sachdev MS, Mehta K, Pandey SK, editors, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2004.

37. **Book Chapter: Chan CK, Lin SG.** *Management of dislocated IOLs by the vitreoretinal approach.* In: Phacoemulsification, Volume 2, Chapter 75, pp 789-798, 3rd edition, Agarwal S, Agarwal At, Agarwal Am, Fine IH, Sachdev MS, Mehta K, Pandey SK, editors, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2004.
38. **Book Chapter: Agarwal Am, Agarwal S, Agarwal At, Pandey SK, Chan CK.** *FAVIT: A technique for removing dropped nucleus during phacoemulsification.* In: Phacoemulsification, Volume 2, Chapter 76, pp 799-803, 3rd edition, Agarwal S, Agarwal At, Agarwal Am, Fine IH, Sachdev MS, Mehta K, Pandey SK, editors, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2004.
39. **Book Chapter: Agarwal Am, Agarwal S, Agarwal At, Pandey SK, Chan CK.** *FAVIT: A technique for removing dropped nucleus during phacoemulsification.* In: Step by Step Phaco, Chapter 7, pp 113-123, 1st edition, Agarwal S, Agarwal A, Agarwal Am, editors, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2005.
40. **Book Chapter: Agarwal Am, Chan CK, Agarwal At, Agarwal S.** *Surgical management of the malpositioned intraocular implant.* In: Step by Step Phaco, Chapter 8, pp 125-154, 1st edition, Agarwal S, Agarwal A, Agarwal Am, editors, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2005.
41. ****Publication: Chan CK, Tarasewicz DG, Lin SG.** *Subconjunctival migration of silicone oil through a Baerveldt pars plana glaucoma implant.* Br J Ophthalmol 2005; 89: 240-241.
42. **Book Chapter: Agarwal Am, Chan CK, Sachdev MS.** *Complications of bimanual phaco.* In: Bimanual Phaco, Mastering the Phakonit/MICS Technique., Chapter 19, pp 179-195, 1st edition, Agarwal Am, editor, Slack Incorporated, Thorofare, New Jersey, 2005.
43. **Book Chapter: Chan CK.** *Managing dislocated lens fragments.* In: Bimanual Phaco, Mastering the Phakonit/MICS Technique., Chapter 20, pp 197-211, 1st edition, Agarwal Am, editor, Slack Incorporated, Thorofare, New Jersey, 2005.
44. ****Publication: Chan CK, Tarasewicz DG, Lin SG.** *Relation of pre-LASIK and post-LASIK retinal lesions and retinal examination for LASIK eyes.* Br J Ophthalmol 2005; 89: 299-301.
45. **Book Chapter: Tarasewicz DG, Chan CK.** *Peripheral retinal degenerative lesions.* In: Handbook of Ophthalmology, Agarwal A et al., editors, Chapter 14, pp 475-486. Slack Incorporated, 2005.
46. **Book Chapter: Chan CK, Tarasewicz DG.** *Retinal detachment.* In: Handbook of Ophthalmology, Agarwal A et al., editors, Chapter 15, pp 487-494. Slack Incorporated, 2005.
47. ****Publication: Arévalo JF, Mendoza AJ, Velez-Vazquez W, Rodriguez FJ, Rodriguez A, Rosales-Meneses JL, Yopez JB, Ramirez E, Dessouki A, Chan CK, Mitra RA, Ramsay RC, Garcia RA, Ruiz-Moreno JM.** *Full-thickness macular hole after LASIK for the correction of myopia.* Ophthalmol 2005; 112: 1207-12.
48. ****Publication: Arévalo JF, Rodriguez FJ, Rosales-Meneses JL, Dessouki A, Chan CK, Mitra RA, Ruiz-Moreno JM.** *Vitreoretinal surgery for macular hole after laser assisted in situ keratomileusis for the correction of myopia.* Br J Ophthalmol 2005; 89:1423-1426.
49. ****Publication: (Member of writing committee)** *Pooled efficacy results from two multinational randomized controlled clinical trials of a single Intravitreal injection of highly purified ovine hyaluronidase (Vitrace®) for the management of vitreous hemorrhage.* Am J Ophthalmol 2005; 140: 573-584.

50. **Publication: Chan CK.** *Temporary haptic externalization helps control IOL repositioning procedure.* Ocular Surgery News, Europe/Asia-Pacific Edition. Volume 17, No. 6, June 2006, 39.
51. ****Publication: Chan CK,** Limstrom SA, Tarasewicz DG, Lin SG. *Ocular features of West Nile virus infection in North America. A study of 14 eyes.* Ophthalmol 2006; 113: 1539-1546.
52. **Book Chapter: Chan CK.** *Managing dislocated lens fragments.* In Agarwal Am, ed. Phaco Nightmares, Conquering Cataract Catastrophies, Chapter 25, pp 325-342, 1st edition, Slacks Incorporated, Thorofare, New Jersey, 2006.
53. **Book Chapter: Chan CK.** *Surgical management of the malpositioned intraocular implant.* In: Agarwal Am ed. Phaco Nightmares, Conquering Cataract Catastrophies, Chapter 26, pp 343-357, 1st edition, , editor, Slacks Incorporated, Thorofare, New Jersey, 2006.
54. **Book Chapter: Chan CK,** Lin SG. *Infectious endophthalmitis.* In: Phaco Nightmares, Conquering Cataract Catastrophies, Chapter 26, pp 359-371, 1st edition, Agarwal Am, editor, Slacks Incorporated, Thorofare, New Jersey, 2006.
55. ****Publication: Chan CK.** *Unilateral retinal granulomatous lesion.* Diagnostic and Therapeutic Challenges. Retina 2007; 27: 101-105.
56. **Book Chapter: Chan CK,** Lin SG. *Management of dislocated lens and lens fragments by the vitreoretinal approach.* In: Mastering The Phacodynamics (Tools, Technology and Innovations), Chapter 56, pp 477-484, 1st edition, A Garg, IH Fine, JL Alió, DF Chang, KR Mehta, JJ Bovet, H Tsuneoka, CK Mehta, editors, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2007.
57. ****Publication (Editorial): Chan CK.** *Ocular manifestation of West Nile virus: a vanishing disease in North America?* Can J Ophthalmol 2007; 42:195-198.
58. ****Publication:** Writing Committee member of the Diabetic Retinopathy Clinical Research Network (Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, **Chan CK,** Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR.). *A Phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.* Ophthalmol 2007; 114:1860–1867.
59. ****Publication: Chan CK,** Hawkins H, Lin SG. *Modified haptic externalizing technique for repositioning dislocated 1-piece acrylic posterior chamber implants.* Can J Ophthalmol 2007; 42: 573-579.
60. **Book Chapter: Agarwal Am,** Agarwal At, Agarwal S, **Chan CK.** *Complications.* In Agarwal S, Agarwal At, Agarwal Am eds. Phacoemulsification, Chapter 3, pp 82-170, 1st edition, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, 2007.
61. ****Publication: Chan CK,** Meyer CH, Gross JG, et al. *Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.* Retina 2007; 27:541-51.
62. ****Publication: Chan CK,** Lin SG. *Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment.* Eur J Ophthalmol 2007; 17: 674-676.

63. ****Publication:** Writing Committee member of the Diabetic Retinopathy Clinical Research Network (Scott IU, Bressler NM, Bressler SB, Browning DJ, **Chan CK**, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group). *Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema*. *Retina* 2008; 28:36-40.
64. ****Publication:** **Chan CK**, Lin SG. *Subfoveal choroidal neovascularization associated with cytomegalovirus retinitis and acquired immune deficiency syndrome*. *Can J Ophthalmol* 2008; 43:486-8.
65. ****Publication:** **Chan CK**, Lin SG, Nuthi ASD, Salib DM. *Pneumatic retinopexy for the repair of retinal detachments: a comprehensive review (1986 to 2007)*. *Surv Ophthalmol* 2008; 53: 443-78.
66. *** Publication:** Meyer CH, **Chan CK**, Clemens C, Holz FG. Estimation on the incidence and OCT risk factors for RPE tears after intravitreal anti-VEGF injections. *Retina Physicians* 2009; Nov. 1-3.
67. **Book Chapter:** **Chan CK**. *Retinal detachment*. In: Color Atlas of Ophthalmology 2nd edition, Agarwal A, ed., Thieme Medical Publishers. New York, New York, 2009.
68. ****Publication:** Scott IU, Blodi BA, Ip MS, Van Veldhuisen PC, Oden NL, **Chan CK**, Gonzalez V, and the SCORE Study Investigator Group. *SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type*. *Ophthalmol* 2009; 116:756-761.
69. ****Publication:** Ip MS, Scott IU, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino MS, **Chan CK**, Gonzalez VH and the SCORE Study Research Group. *A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5*. *Arch Ophthalmol* 2009;127:1101-1114.
70. ****Publication:** Scott IU, Ip MS, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, **Chan CK**, Gonzalez V, Singerman LJ, Tolentino MS and the SCORE Study Research Group. *A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with Standard Care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6*. *Arch Ophthalmol* 2009;127:1115-1128.
71. **Book Chapter:** **Chan CK**, Tarasewicz DG, *Surgical Retina*. In Agarwal A, Jacobs S eds. Color Atlas of Ophthalmology 2nd edition, Chapter 10, pp 288-321, Thieme Medical Publishers. New York, New York, 2009.

72. ****Publication: Chan CK**, Abraham P, Meyer CH, Kokame GT, Kaiser PK, Rauser ME, Gross JG, Nuthi ASD, Lin SG., Daher NS. *Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears with intravitreal bevacizumab injections*. *Retina* 2010;30:203-211.
73. **Book Chapter: Jacob S, Kumar DA, Satish K, Chan CK, Agarwal A**, *Posterior capsular rupture and its management*. In Agarwal A, Lindstrom RL, eds. *Microincisional cataract surgery: The Art and Science*. Thorofare, New Jersey, SLACK Incorporated; 2010:183-192.
74. ****Publication: Sarraf D, Vyas N, Jain A, Bui A, Kertes P, Freund KB, Chan CK**. *Triamcinolone associated crystalline maculopathy*. *Arch Ophthalmol* 2010; 128: 685-690.
75. ****Publication: Chan CK, Ip MS, Van Veldhuisen PC, Oden NL, Scott IU, Blodi BA, Tolentino MS and the SCORE Study Research Group**. SCORE Study Report #11: Incidences of Neovascular Events in Eyes with Retinal Vein. *Ophthalmol* 2011; 118: 1364-1372.
76. ****Publication: Chan CK, P. Abraham, D Sarraf**, High-dose ranibizumab therapy for vascularized pigment epithelial detachment. *Eye*. Fast Track Paper and Advance Online Publication 11 May 2012; DOI: 10.1038/eye.2012.90; Epub 2012 May 11; *Eye* 2012; 26:882-885.
77. ****Publication: Chan CK, Sarraf D**. *Response to the letter by Talks et al (June 27, 2012) on High-dose Ranibizumab Therapy for Vascularized Pigment Epithelial Detachment*. *EYE: Advance Online Publication* 19 October 2012; DOI:10.1038/eye.2012.209; Epub 2012 Oct 19, 2012 (Letter).
78. **Book Chapter: Condon, G, Chan CK, Agarwal A**. *Management of dislocated IOL's*. In Agarwal A. ed. *Posterior capsular rupture, a practical guide to prevention and management*. Thorofare, New Jersey, SLACK Incorporated; 2013; pending.
79. **Book Chapter: Chan CK**. *Management of dislocated IOL's, Postoperative endophthalmitis*. In Agarwal A. ed. *Posterior capsular rupture, a practical guide to prevention and management*. Thorofare, New Jersey, SLACK Incorporated; 2013; pending.
80. ****Publication: Sarraf D, Chan CK, Rahimy E, Abraham P**. Prospective evaluation of the incidence and risk factors for the development of RPE tears after high-and low-dose ranibizumab therapy. *Retina* 2013; 33:1551-15.
81. ****Publication: Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Stone T, for the Diabetic Retinopathy Clinical Research Network**. *Exploratory Analysis of Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial*. *JAMA Ophthalmol* 2013;131:1033-1040.
82. **Book Chapter: Condon GP, Chan CK, Agarwal A**. *Management of Dislocated Intraocular Lenses*. In: Agarwal A, Jacob S, eds. *Posterior Capsular Rupture: A Practical Guide to Prevention and Management*. 1st ed. Thorofare, NJ: SLACK Incorporated; 2013:165-183.

83. **Book Chapter: Chan CK.** Postoperative Endophthalmitis. In: Agarwal A, Jacob S, eds. *Posterior Capsular Rupture: A Practical Guide to Prevention and Management*. 1st ed. Thorofare, NJ: SLACK Incorporated; 2013:211-220.
84. ****Publication: Chan CK,** Abraham P, Sarraf D, Nuthi ASD, Lin SG, McCannel CA. *Earlier therapeutic effects associated with high-dose (2.0 mg) ranibizumab for treatment of vascularized pigment epithelial detachment in age-related macular degeneration*. Eye 2014; (official journal of The Royal College of Ophthalmologists, NPG Nature Publishing Group). 3 October 2014; doi:10.1038/eye.2014.233; 2015;29:80-87.
85. ****Publication: Chan CK,** Jain A, Sadda S and Varshney N. *Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (An American Ophthalmological Society Thesis)*. Trans Am Ophthalmol Soc 2014;112:160-198.
86. ****Publication: Chen X,** Al-Sheikh M, **Chan CK,** Hariri AH, Abraham P, Lalezary M, Lin SG, Sadda S, Sarraf D. *Type 1 versus type 3 neovascularization in PEDs associated with AMD after anti-VEGF therapy: a prospective study*. Retina 2016 Dec;36 Suppl 1:S50-S64. doi: 10.1097/IAE.0000000000001271.
87. ****Publication: Chan CK,** Crosson JN, Mein CE. *Pneumatic vitreolysis for relief of vitreomacular traction*. Retina 2017; 37:1820-1831; Jan 17. doi: 10.1097/IAE.0000000000001448. [Epub ahead of print]
88. ****Publication: Crosson JN,** **Chan CK,** Mein CE. *Pneumatic vitreolysis for treatment of focal vitreomacular traction (Clinical Trials, Future Pathways)*. Retina Times Summer 2017;35(69): 24-26.
89. ****Editorial/Review: Chan CK,** Mein CE, Crosson JN. *Pneumatic vitreolysis for managing symptomatic focal vitreomacular traction*. J Ophthalmic Res 2017; 12:419-423.
90. ****Publications: Chan CK,** Sarraf D, Abraham P. *Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes*. Eur J Ophthalmol 2018; In press.
91. ****Publication: Khanani AM,** **Chan CK,** Regillo RD. *Considering Treatment Options for Vitreomacular Traction*. BLOCK TIME. Editors J Hsu, M Fineman, Retina Times, 2019; 37:30-34.
92. ****Publication: Crosson JN,** Thomley M, **Chan CK,** Mein CE. *Loculated subretinal fluid after pneumatic vitreolysis*. Amer Journal Ophthalmol Case Reports 2019; 15:100462.
93. **** Publication: Scott IU,** Oden NL, VanVeldhuisen PC, Ip MS, Blodi B, **Chan CK.** for the SCORE2 Investigator Group. SCORE2 Report 10: *Month 24 Outcomes after Treatment Initiation with Anti-VEGF Therapy for Macular Edema due to Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2 12 Months after Cessation of SCORE2 Protocol-Defined Treatment Schedule*. JAMA Ophthalmology (2019 Oct 10. doi: 10.1001/jamaophthalmol.2019.3947).

94. **** Publication:** Kashani AH, Uang J, Mert M, Rahhal F, Chan CK, Avery RL, Dugel P, Chen S, Lebkowski J, Humayun MS. *Surgical method for implantation of a biosynthetic RPE monolayer for advanced dry age-related macular degeneration (AMD): Experience from a Phase 1/2a Study.* *Ophthalmology Retina* 2020;4: 264-273.
95. **** Publication:** Lee D, Chan CK. *Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®).* *Amer J Ophthalmol Case Reports* 2020; 19:1-4; DOI:10.1016/j.ajoc.2020.100725
96. **** Publication:** Lee D, Chan CK, *Post-hoc Analysis of Single Nucleotide Polymorphisms Profile for Eyes with Vascularized Pigment Epithelial Detachment due to ARMD.* *Eur J Ophthalmol* 2020; DOI: 10.1177/1120672120932829.
97. **** Publication:** Ng C, Chan CK, Abraham P, Hafner A. *Single nucleotide polymorphism profiles associated with three common phenotypes of advanced age-related macular degeneration* [letter to editor]. *Acta Ophthalmol* 2020; in press.
98. **** Publication:** Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Chen S, Chan CK, Dugel P, Ingram A, Dang W, Lin C-M, Mitra D, Zhu D, Martinez JC, Bailey J, Arnold C, Faynus M, Pennington BO, Rao N, Johnson LV, O’Clegg D, Hinton DR, Humayun MS. *Survival of an HLA mismatched, bioengineered RPE implant in dry age-related macular degeneration: implications for donor tissue choice.* *Science Translational Medicine*, under review
99. ****Publication:** Chan CK, Sarraf D, Abraham P, Lalezary M, Lin SG, Chen X, Gupta Nittala M, Sadda S. *Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN Study.* *Am J Ophthalmol Case Rep* 2020 Dec; 20: 100916. Published online 2020 Sep 18 doi: 10.1016/j.ajoc.2020.100916.
100. ****Publication:** Chan CK, Mein CE, Beaulieu WT et al. on behalf of the DRCR Retina Network. *Pneumatic vitreolysis with perfluoropropane for vitreomacular traction with or without macular hole. DRCR Retina Network Protocols AG and AH.* *Ophthalmology* 2021 May 12;S0161-6420(21)00353-5. doi: 10.1016/j.ophtha.2021.05.005. Online ahead of print.
101. ****Publication:** Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Chen S, Chan C, Palejwaha N, Ingram A, Dang W, Lin C-M, Mitra D, Pennington BO, Arnold C, Faynus M, Bailey J, Mohan S, Rao N, Johnson LV, Clegg DO, Hinton DR, Humayun MS. *One Year Follow-up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration* *Transl Vis Sci Technol* 2021 Aug 12;10(10):13. Doi:10.1167/tvst.10.10.13.
102. ****Publication:** Kashani AH, Lebkowski JS, Hinton DR, Zhu D, Faynus MA, Chen S, Rahhal FM, Avery RL, Saleh-Had H, Chan CK, Palejwala N, Ingram A, Dang W, Lin C-M, Mitra D, Martinez-Camarillo JC, Bailey J, Arnold C, Pennington B, Rao N, Johnson LV, Clegg DO, Humayun MS. *Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration.* *Stem Cell Reports* 2022, 17:1-11.
- 103.

****Publication:** Chan CK, Lalezary M, Abraham P, Elman M, Beaulieu WT, Lin SG, Khurana RN, Bansal AS, Wieland MR, Palmer JD, Chang LK, Lujan B, Yiu G., on behalf of the PREVENT Study Group. *Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes A Randomized Clinical Trial* Ophthalmol Retina 2022; 6(6): 484-494 doi: 10.1016/j.oret.2022.01.019.Epub 2022 Feb 1.

104. ****Publication:** Chan CK, Beaulieu WT, Lujan BJ, Lalezary M et al. Impact of prophylactic ranibizumab to prevent neovascular age-related macular degeneration on eyes with intermediate age-related macular degeneration. *Transl Vis Sci Technol* 2023; 12(9): 1. Published online 2023 Sep 1. Doi: 10.1167/tvst.12.9.1
105. ****Publication:** Chan CK, Henao, M. Decoding scleral structures with polarized light [Invited Commentary]. *JAMA Ophthalmol* 2024;142(4):319-320. Doi:10.1001/jamaophthalmol.2024.0199.

SERVICE ACTIVITIES

1. Canvasback project in Marshall Islands: performed first eye laser treatment and taught laser techniques to local ophthalmologists on the Marshall Islands. Set up first laser machine (Air-cooled Britte Laser) in Majuro, Marshall Islands. Apr 1987.
2. **Visiting professor ORBIS International:**
 - Urumqi, Xinjiang Province, China Jul 5-9, 1999
 - Chengdu, Sichuan Province, China Jun 2000
 - First Affiliated Hospital of Fujian Medical College, Fuzhou, Fujian Province, China. Mar 2003
3. Lectures at Braille Institute on “Macular Degeneration, current concepts and treatment.” Rancho Mirage, CA. Jan 30, 1991; Feb 10 1995; Feb 27, 1997
4. Publication in the “Living” section of newspaper, The Desert Sun. Full page article: “Focus on the Future”. Jul 23, 1992
5. Discussant: “Anti-angiogenesis therapy, new advances in treatment of retinal diseases” In: American Health Journal KVCR PBS ONE TV station, Southern California, USA. Sep 2006
6. Article introducing the Coachella Valley and Palm Springs in anticipation for the ASRS 25th anniversary and annual meeting 2007, for the Leisure and Travel section of Retina Times, Aug issue. Aug, 2007
7. Lecture on diabetic retinopathy: “Current concepts on management of diabetic retinopathy; latest clinical trials” on “Day of Hope” sponsored by the Coachella Valley Diabetic Club, at Annenberg Educational Center, Eisenhower Medical Center, Rancho Mirage, California. Apr 19, 2008
8. Lecture to community physicians.”Overview of Abicipar Pegol (DARPINTM) in neovascular AMD”, “Treatment of vitreoretinal traction with pneumatic vitreolysis”; sponsored by Allergan Inc., Fleming Steak House, Rancho Mirage, CA, March 2, 2017.
9. Lecture to community physicians. “New drugs and therapeutic targets for treatment of exudative age-related macular degeneration”; sponsored by Allergan Inc. Fleming Steak House, Rancho Mirage, CA, August 3, 2017.

10. American Board of Ophthalmology, oral board examiner, October 5, 6, and 7, 2018, Palace Hotel, San Francisco, CA.
11. American Board of Ophthalmology, oral board examiner, September 12, and 13, 2020. Virtual examination session.
12. American Board of Ophthalmology, oral board examiner, March 20, 21, 2021. Virtual examination session.
13. American Board of Ophthalmology, oral board examiner, October 23, 24, 2021.; also 2022 Virtual examination session.
14. American Board of Ophthalmology, oral board examiner, June 8,9, 2024.
15. American Board of Ophthalmology, oral board examiner, Nov 9,10, 2024.
16. American Board of Ophthalmology, oral board examiner, May 1,2,4, 2025 (pending)

LECTURES AND FLUORESCCEIN/OCT CONFERENCES

For Ophthalmology residents and medical students at Loma Linda University (**Partial list**):

1. **03-10-93:** Central serous chorioretinopathy (CSC); premacular fibrosis; macular holes
2. **09-15-93:** AIDS
3. **11-10-93:** Retinal detachment surgery
4. **03-9-94:** FA conference
5. **03-29-95:** Birdshot chorioretinopathy and Stargardt disease
6. **10-04-95:** Indocyno-green (ICG) angiography
7. **01-03-96:** ICG angiography
8. **03-06-96:** ICG angiography
9. **06-05-96:** ICG angiography
10. **08-01-96:** ICG angiography
11. **02-19-97:** Other macular diseases
12. **05-28-97:** AIDS
13. **10-15-97:** Choroidal tumors
14. **04-08-98:** FA conference: Stargardt; talc emboli
15. **09-09-98:** AIDS
16. **02-24-99:** Lesions of the retinal pigment epithelium (RPE)
17. **06-02-99:** Lesions of the retinal pigment epithelium (RPE)
18. **10-06-99:** Lesions of the RPE and choroid
19. **01-12-00:** Other macular lesions including CSR; macular edema and macular holes.
20. **04-19-00:** Diabetic retinopathy
21. **08-09-00:** Lesions of the retinal pigment epithelium (RPE)
22. **05-30-01:** Choroidal tumors
23. **07-25-01:** Macular diseases: CSR; CME; Macular holes

24. **09-19-01:** Photodynamic therapy for neovascular AMD
25. **10-31-01:** Retinal detachment surgery
26. **11-06-02:** Choroidal tumors
27. **02-12-03:** Ocular photodynamic therapy
28. **05-28-03:** Scleral buckling and vitrectomy techniques
29. **09-10-03:** Other macular diseases: CSR; macular edema; branch retinal vein occlusion
30. **10-22-03:** AIDS
31. **12-03-03:** Tumors of the fundus
32. **02-04-04:** Photodynamic therapy
33. **05-19-04:** Fundus lesions of the RPE
34. **06-09-04:** Retinal surgery
35. **09-01-04:** Central serous chorioretinopathy; West Nile virus retinopathy
36. **11-24-04:** Diabetic retinopathy
37. **09-07-05:** Retinal detachment surgery: Scleral buckling and vitrectomy
38. **11-30-05:** Photodynamic therapy
39. **02-08-06:** Lesions of the retinal pigment epithelium (RPE)
40. **04-19-06:** Ocular findings associated with AIDS
41. **06-14-06:** Central serous chorioretinopathy
42. **08-16-06:** Macular hole surgery
43. **11-29-06:** Diabetic retinopathy
44. **12-20-06:** CSC, Macular edema, BRVO
45. **08-08-07:** Corticosteroid therapy: AIDS and HIV retinopathy
46. **02-13-08:** Lesions of the retinal pigment epithelium (RPE)
47. **09-10-08:** Diabetic retinopathy
48. **03-30-09:** Potpourri of RPE lesions
49. **02-21-10:** Annual mock board examiner at LLU Ophthalmology department
50. **04-16-10:** Bilateral diffuse uveal melanocytic proliferative (BDUMP)
51. **04-16-10:** Idiopathic uveal effusion syndrome (IUES); White dot syndrome of the fundus
52. **09-17-10** Peripheral retinal lesions
53. **09-17-10** Diagnosis and treatment of retinal breaks and detachment; scleral buckling
54. **10-29-10** Developmental vitreoretinal abnormalities
55. **11-12-10** Retina subspecialty day review: Posterior segment trauma: Blunt injuries; mechanisms of injuries
56. **11-12-10** Retina subspecialty day review: Posterior segment trauma: Penetrating injuries; Diagnostic work-up and management
57. **12-31-12** Lesions involving the retinal pigment epithelium, Part 1
58. **02-13-13** Lesions involving the retinal pigment epithelium, Part 2.
59. **01-17-14** Lesions of the retinal pigment epithelium Part 1
60. **03-28-14** Lesions of the retinal pigment epithelium Part 2
61. **01-16-15** Bilateral diffuse uveal melanocytic proliferation (BDUMP)
Idiopathic uveal effusion syndrome (IUES); White dot syndrome of the Fundus
62. **03-20-15** Peripheral retinal lesions, a clinicopathological correlation and analysis;
Controversies in prophylactic treatment for peripheral retinal lesions
63. **08-27-15** First-year resident lecture series: Indirect ophthalmoscopy, the art and practice.
64. **08-27-15** First-year resident lecture series: Retinal detachment

65. **08-27-15** First-year resident lecture series: Peripheral retinal lesions
66. **09-08-15** Journal club; discussant on 4 retinal published reports
67. **12-11-15** Retina Grand Rounds: 1) chaired discussion on case presentation by residents; 2) Presentation: OCT and Vision Results at Six Months after Switching to Aflibercept for Patients on Prior Ranibizumab or Bevacizumab Treatment for Exudative AMD
68. **01-06-16** Retina Grand Rounds: 1) OCT and Vision Results at Six Months after Switching to Aflibercept for Patients on Prior Ranibizumab or Bevacizumab Treatment for Exudative AMD; 2) Intraocular Pharmacokinetic and Pharmacodynamic Profiles in Patients Receiving Intravitreal Aflibercept Therapy for Neovascular Age-related Macular Degeneration
69. **10-21-16** Indirect ophthalmoscopy and methods of locating retinal breaks associated with a rhegmatogenous retinal detachment; central retinal vein occlusion; central serous chorioretinopathy.
70. **04-28-17** Diabetic retinopathy.
71. **05-04-17** Choroidal disease.
72. **01-03-2018** Grand Round: New Drug and Therapeutic Targets for Neovascular Age-related Macular Degeneration
73. **10-12-2018** Choroidal hemangioma; bilateral diffuse uveal melanocytic proliferation (BDUMP) ; idiopathic uveal effusion syndrome (IUES); central serous chorioretinopathy (CSC).
74. **01-10-2020** Differential diagnoses of fundus lesions involving the RPE.
75. **04-24-2020** Peripheral retinal lesions, retinal tears and detachment (Virtual via ZOOM).
76. **05-13-2020** Central serous chorioretinopathy (CSC); Indirect ophthalmoscopy (via ZOOM).
77. **01-14-2022** Diabetic retinopathy, diagnosis, classification, terminology, clinical studies; DRCR Retina Network’s clinical studies.
78. **01-14-2022** Hemangioma, bilateral diffuse uveal melanocytic proliferation (BDUMP), hemangioma, idiopathic uveal effusion syndrome; central serous chorioretinopathy, updates.
79. **01-12-2024** Diabetic retinopathy, diagnosis, classification, terminology, clinical studies; DRCR Retina Network’s clinical studies.
80. **01-12-2024** Hemangioma, bilateral diffuse uveal melanocytic proliferation (BDUMP), hemangioma, idiopathic uveal effusion syndrome.

SCIENTIFIC MEETINGS (partial list):

- Oct 1982:** American Academy of Ophthalmology (AAO) annual meeting, San Francisco, CA.
- Feb 1983:** Mid-winter meeting (Research Study Club) sponsored by Doheny Eye Institute USC, Los Angeles, CA.
- May 1984:** Annual Jules Stein meeting at UCLA, Los Angeles, CA.
- May 1985:** Annual Eye Alumni meeting, Washington Univ., St. Louis, MO.
- Oct 1985:** AAO annual meeting, San Francisco, CA.
- Oct 1986:** AAO annual meeting, New Orleans, LA.

7. **Jan 1987:** West Coast Retina Study Club annual meeting, HI.
8. **Jun 1987:** Paul Cibis 7th biennial meeting, Montreal, Canada.
9. **Mar 17, 1988:** West Coast Retina Study Club annual meeting, San Francisco, CA.
10. **Mar 18-19, 1988:** Retinal Symposium (Sponsored by Schatz, McDonald, Johnson, et al.) San Francisco, CA.
11. **Oct 8-12, 1988:** AAO annual meeting, Las Vegas, NV.
12. **Nov 30-Dec 3, 1988:** Vitreous Society 6th annual meeting Scottsdale, AZ.
13. **Oct 1989:** AAO annual meeting, New Orleans, LA.
14. **Jun 28, 1990:** Tri-County Eye Society meeting on “Practice Management”. San Bernardino Hilton, San Bernardino, CA.
15. **Oct 26-27, 1990:** Advanced Retina Vitreous meeting, Emory University, Atlanta, GA.
16. **Oct 28-31, 1990:** AAO annual meeting, Atlanta, GA.
17. **Jan 21-24, 1991:** Vitreous Society 9th annual meeting, Hawaii, HI.
18. **Feb 15-16, 1991:** Western Retina Study Club annual meeting, Seattle, WA.
19. **May 19-20, 1991:** Paul Cibis Club 9th biennial meeting, Napa, CA.
20. **Oct 12-19, 1991:** AAO and Pan American Academy of Ophthalmology annual meeting, Anaheim, CA.
21. **Nov 2, 1991:** NORCAL Continuing Education seminar, “Prescription Medication: Problems and Solutions Relating to Patient Care.” Hyatt Grand Champions, Indian Wells, CA.
22. **Feb 17-18, 1992:** Western Retina Study Club annual meeting, Kauai Westin Hotel, Kauai, HI.
23. **May 3-8, 1992:** Association for Research in Vision and Ophthalmology (ARVO) annual meeting, Sarasota, FL.
24. **Oct 18-21, 1992:** Vitreous Society 10th annual meeting, Laguna Niguel, CA.
25. **Oct 24, 1992:** NORCAL Meeting: Diagnosing Cancer, Los Angeles, CA.
26. **Nov 9-12, 1992:** AAO annual meeting, Dallas, TX.
27. **Dec 7, 1992:** Riverside Community Hospital Fluorescein Conference, Riverside, CA.
28. **Feb 7, 1992:** “Frontiers in Ophthalmology”, Loma Linda University, Loma Linda, CA.
29. **Feb 19, 1993:** Tri-County Eye Society, Donald Frambach, M.D.: “Scanning Laser Ophthalmoscopy: An Overview”, San Bernardino Hilton, San Bernardino, CA.
30. **May 1-6, 1993:** ARVO annual meeting, Sarasota, FL.
31. **Jun 9-12, 1993:** Paul Cibis 10th biennial vitreoretinal symposium, Santa Fe, NM.
32. **Sep 11, 1993:** Conference sponsored by Cypress Foundation. NORCAL meeting on liability of HIV/AIDS, Rancho Mirage Mission Hills, Rancho Mirage, CA.
33. **Nov 15-19, 1993:** AAO annual meeting, Chicago, IL.
34. **Nov 29-Dec. 4, 1993:** Vitreous Society 11th annual meeting, St. Thomas, U.S. VI.
35. **Jan 28, 1994:** Western Retina Study Club annual meeting, Phoenix, AZ.

36. **May 1-6, 1994:** ARVO annual meeting, Sarasota, FL.
37. **Nov 2, 1994:** OMIC Professional Liability and Risk Management Review for Ophthalmology, AAO Annual Meeting, San Francisco, CA.
38. **Oct 29 – Nov. 3, 1994:** AAO annual meeting, San Francisco, CA.
39. **Oct 26 - Nov 2, 1995:** AAO annual meeting, Atlanta, GA.
40. **Oct 25-26, 1996:** Pre-AAO retinal symposium: Vitreoretinal Frontiers, Chicago, IL.
41. **Oct 24-31, 1996:** AAO annual meeting, Chicago, IL.
42. **Oct 25-26, 1997:** Pre-AAO retinal symposium: Vitreoretinal Update, San Francisco, CA.
43. **Oct 25-29, 1997:** AAO annual meeting, San Francisco, CA.
44. **Nov 7-8, 1998:** Pre-AAO retinal symposium: Vitreoretinal Update, New Orleans, LA.
45. **Nov 7-11, 1998:** AAO annual meeting, New Orleans, LA.
46. **Mar 13, 1999:** Western Retina Study Club annual meeting, Newport Beach, CA.
47. **Sep 21-25, 1999:** The Vitreous Society 17th annual meeting, Rome, Italy.
48. **Oct 23-28, 1999:** AAO annual meeting, Orlando, FL.
49. **Feb 25-26, 2000:** Western Retina Study Club annual meeting, Stevenson, WA.
50. **Oct 20-21, 2000:** Pre-AAO Retina Subspecialty Update, Dallas, TX.
51. **Oct 23-26, 2000:** AAO annual meeting, Dallas, TX.
52. **Jun 27-30, 2001:** Paul Cibis Club 14th vitreoretinal symposium, Napa, CA.
53. **Nov 09-10, 2001:** Reviewed CD ROM for 2001 Pre-AAO Retina Subspecialty Symposium Retina 2001: A Retina Odyssey, New Orleans, LA.
54. **Nov 11-14, 2001:** AAO annual meeting, New Orleans, LA.
55. **Mar 23, 2002:** Western Retina Study Club annual meeting, Snoqualmie, WA.
56. **Apr 28, 2002:** Resident and Alumni Research Day, Loma Linda, CA.
57. **Sep 28- Oct 2, 2002:** Retina Congress 2002, combined meeting of the Retina and Vitreous Societies, San Francisco, CA.
58. **Oct 18-19, 2002:** Pre-AAO retinal symposium (Retina 2002: Giant Steps- A Look at the Past, An Eye on the Future), Orlando, FL.
59. **Oct 20-23, 2002:** AAO and Pan American Association of Ophthalmology annual meeting, Orlando, FL.
60. **May 2, 2003:** Loma Linda University, Department of Ophthalmology Resident and Alumni Research Day, Loma Linda, CA.
61. **Jun 25-28, 2003:** Paul Cibis 15th biennial vitreoretinal symposium, Aspen, CO.
62. **Aug 16-20, 2003:** Vitreous Society 21st annual meeting, New York, NY.
63. **Nov 14-15, 2003:** Pre-AAO retinal symposium (The Retina Debates), Anaheim, CA.
64. **Nov 15-18, 2003:** AAO annual meeting, Anaheim CA.

65. **Feb 13-14, 2004:** Western Retina Study Club annual meeting, Whistler, BC, Canada.
66. **Aug 16-20, 2004:** Vitreous Society 22nd meeting, San Diego, CA.
67. **Sep 30-Oct 3, 2004:** The Retina Society 37th annual scientific session, Baltimore, MD.
68. **Oct 22-23, 2004:** Pre-AAO retinal symposium (Everything You Ever Wanted to Know About Retina...), New Orleans, LA.
69. **Oct 23-26, 2004:** AAO annual meeting, New Orleans, LA.
70. **Mar 12, 2005:** Western Retina Study Club annual meeting, Phoenix, AZ.
71. **Jul 16-20, 2005:** Vitreous Society 23rd annual meeting, Montreal, Canada.
72. **Sep 15-18, 2005:** The Retina Society 38th annual scientific session, San Diego, CA.
73. **Oct 15-18, 2005:** AAO annual meeting, Chicago, IL.
74. **Sep 9-13, 2006:** ASRS 24th annual meeting and European Vitreoretinal Society, Palais Des Festivals, Cannes, France (26 credit hours).
75. **Oct 15-20, 2006:** Combined meeting of the Club Jules Gonin and The Retina Society 39th annual scientific session, Capetown International Convention Centre, Capetown, South Africa.
76. **Nov 11-14, 2006:** AAO and the Asia Pacific Academy of Ophthalmology (APAO) annual meeting, Las Vegas, NV.
77. **Dec 01, 2006:** Pain Management, sponsored by the California Medical Association, The Disneyland Hotel, Anaheim, CA.
78. **Mar 4, 2007:** Loma Linda University Alumni Postgraduate Convention, Loma Linda, CA.
79. **Sept 27-30:** The Retina Society 40th annual scientific session, Intercontinental Boston Hotel, Boston, MA.
80. **Sep 25-28, 2008:** The Retina Society 41st annual scientific session, Scottsdale, AZ.
81. **Oct 10, 2008:** The Retina Center at Pali Momi, “Celebrating 15 years”, JW Marriott Ihilani Resort & Spa – Ko’Olina Resort – Oahu, HI.
82. **Oct 11-15, 2008:** Meeting of the ASRS, Maui, HI.
83. **Nov 07-08, 2008:** AAO Subspecialty Day (Retina 2008: Vistas and Viewpoints), Atlanta, GA.
84. **Nov 08-11, 2008:** AAO and European Society of Ophthalmology (ESO) annual meeting, Atlanta, GA.
85. **May 03-07, 2009:** ARVO annual meeting, Broward County Convention Center, Fort Lauderdale, Florida (35.25 Credit hours).
86. **May 22, 2009:** Loma Linda University Dept of Ophthalmology Resident Research Symposium, Loma Linda, CA.
87. **Sept 29-Oct 04, 2009:** Retina Congress (Combined meeting of the ASRS, Retina Society, and Macula Society), Sheraton NY Hotel and Towers, New York, NY.
88. **Oct 22, 2009:** 2nd annual meeting Gass Society, Palace Hotel, San Francisco, CA.
89. **Oct 23-24, 2009:** AAO Subspecialty Day (Retina 2009: The Cutting Edge), San Francisco, CA.
90. **Oct 24-26, 2009:** AAO and Pan American Association of Ophthalmology PAAO annual meeting, Moscone Convention Center, San Francisco, CA.
91. **May 02-06, 2010:** ARVO annual meeting, Broward County Convention Center, Greater Fort Lauderdale, FL.
92. **Aug 28-Sept 01, 2010:** ASRS annual meeting, Vancouver Convention Centre, Vancouver, BC, Canada.
93. **Sept 23-26, 2010:** The Retina Society 43rd annual scientific session, St. Francis Hotel, San Francisco, CA.
94. **Oct 14:** 3rd annual meeting Gass Society, Hotel Sass, Chicago, IL.

95. **Oct 15-16, 2010:** AAO Subspecialty Day (Retina 2010: A Panretinal Perspective), McCormick Place, Chicago, IL.
96. **Oct 16-19, 2010:** AAO and Middle East Africa Council of Ophthalmology (MEACO) annual meeting, McCormick Place, Chicago, IL.
97. **Nov 03-06, 2010:** Club Jules Gonin's annual meeting, Kyoto, Japan.
98. **May 01-04, 2011:** ARVO annual meeting, Broward County Convention Center, Greater Fort Lauderdale, FL.
99. **Aug 20-24, 2011:** ASRS annual meeting, Shynes Convention Center, Boston, MA.
100. **Sept 21-25, 2011:** The Retina Society 44th scientific session and Società Italiana della Retina, Westin Excelsior Hotel, Rome, Italy.
101. **Oct 20-21, 2011:** AAO Subspecialty Day (Retina 2011: The Magical World of Retina), Orlando, FL.
102. **Oct 22-25, 2011:** AAO annual meeting, Orange County Convention Center, Orlando, FL.
103. **May 06-09, 2012:** ARVO annual meeting, Broward County Convention Center, Greater Fort Lauderdale, FL.
104. **June 11-15, 2012:** The 35th annual meeting of the Macula Society, The David Citadel Hotel, Jerusalem, Israel.
105. **June 22-23, 2012:** XXVIIIth Congress of the Club Jules Gonin, Harpa Concert and Conference Centre, Reykjavík, Iceland.
106. **August 25-29, 2012:** 30th anniversary annual meeting of the American Society of Retina specialists, Aria Resort, Las Vegas, NV.
107. **Nov 8, 2012:** 4th annual meeting Gass Society, Mile North Hotel, Chicago, IL.
108. **Nov 9-10, 2012:** AAO Subspecialty Day (Retina 2012: The Winds of Change), McCormick Place, Chicago, IL.
109. **Nov 10-13.** AAO/APAO joint annual meeting, McCormick Place, Chicago, IL.
110. **Feb 27-Mar 2, 2013:** 36th annual Macula Society Meeting, St. Regis Monarch Beach Hotel, Dana Point, CA.
111. **May 05-09, 2013:** ARVO annual meeting, Washington State Convention Center, Seattle, WA.
112. **August 24-28, 2013:** 31st Annual meeting of the American Society of Retina Specialists, Toronto, Ontario, Canada.
113. **Sept 26-29, 2013:** 46th annual scientific meeting, the Retina Society, Beverly Hills, CA.
114. **Nov 15-16, 2013:** Retina Subspecialty Day 2013: Let the Good Times Roll, Ernest N. Morial Convention Center, New Orleans, LA.
115. **Nov 17-19, 2013:** Annual meeting of the American Academy of Ophthalmology, Ernest N. Morial Convention Center, New Orleans, LA.
116. **February 19-22, 2013:** 37th annual meeting of Macula Society, Ocean Reef Club, Key Largo, FL.
117. **March 9, 2014:** Loma Linda University Alumni Postgraduate Convention, Loma Linda California
118. **March 28-29, 2014:** Pacific Retina Club, Grand Hyatt, San Francisco, CA.
119. **May 4-8, 2014:** ARVO annual meeting, Orlando Convention Center, Orlando, FL.
120. **Aug 9-13, 2014:** ASRS annual meeting, San Diego, CA.
121. **Sept 3-6, 2014:** Club Jules Gonin biennial meeting, Zürich, Switzerland.
122. **Oct 16, 2014:** Fifth Annual Gass Fellowship Society Meeting, OMNI Hotel, Chicago, IL.
123. **Oct 17-18, 2014:** AAO Subspecialty Day (Retina 2014: Reaching New Heights), McCormick Place, Chicago, IL.
124. **Oct 18-20, 2014:** AAO annual meeting, McCormick Place, Chicago, IL.
125. **Feb 25-28, 2015:** Macula Society annual meeting, Scottsdale, AZ.

126. **March 31-April 4, 2015:** Asia-Pacific Academy of Ophthalmology and Chinese Ophthalmological Society, Guangzhou, China.
127. **May 03-07, 2015:** ARVO annual meeting, Colorado Convention Center, Denver, CO.
128. **May 14-17, 2015:** AOS annual meeting, The Hotel Viking, Newport, RI.
129. **Oct 7-11, 2015:** The Retina Society, Intercontinental Paris-Le Grand Hotel, Paris, France.
130. **Nov 12, 2015:** Gass Fellowship meeting, Las Vegas, NV.
131. **Nov 13-14, 2015:** AAO Subspecialty Day (Upping the Ante), Las Vegas, NV.
132. **Nov 13-17, 2015:** AAO annual meeting, Sands Expo/Venetian, Las Vegas, NV.
133. **Feb 24-27, 2016:** Macula Society annual meeting, Miami Beach, Fl.
134. **May 19-22, 2016:** American Ophthalmological Society annual meeting, Colorado Springs, CO.
135. **July 6-9, 2016:** Club Jules Gonin meeting, Bordeaux France
136. **August 9-14,2016:** American Society of Retina Specialists, San Francisco, CA.
137. **Sept 14-17, 2016:** The Retina Society, San Diego, CA.
138. **Oct 15-18, 2016:** AAO annual meeting, McCormick’s Place, Chicago, IL.
139. **Dec 8-10, 2016:** APVRS annual meeting, Bangkok, Thailand.
140. **May 7-9, 2017:** ARVO annual meeting, Baltimore, MD (registered).
141. **May 18-21, 2017:** AOS annual meeting, Homestead Resort, Hot Springs, VA.
142. **June 7-10, 2017:** Macula Society annual meeting, Shangri-La Hotel, Singapore.
143. **Aug 11-15, 2017:** ASRS annual meeting, Hynes Convention Center, Boston, MA.
144. **Aug 18-19, 2017:** DRCCR.net semi-annual summer meeting, Airport Marriott, Houston, Tx
145. **Oct 05-08, 2017:** The Retina Society annual meeting, Fairmont Copley Plaza Hotel, Boston, MA.
146. **Nov 9, 2017:** Gass Fellowship meeting, Royal Sonesta Hotel, New Orleans, LA.
147. **Nov 10, 2017:** Pre-AAO Retina Subspecialty Day, N. Morial Convention Center, New Orleans, LA.
148. **Nov 11-14, 2017:** AAO annual meeting, N. Morial Convention, Center, New Orleans, LA.
149. **Dec 8-10, 2017:** APVRS annual meeting, Kuala Lumpur, Malaysia.
150. **Jan 3, 2018:** Grand Round, Loma Linda University Eye Institute
151. **Jan 25-27, 2018:** DRCCR.net annual Winter meeting, Tampa, Fl.
152. **Feb 03, 2018:** Doheny/UCLA Evolving imaging and treatment modalities conference.
153. **Feb 21-24, 2018:** Macula Society 41st annual meeting, Beverly Hills, CA.
154. **May 17-20, 2018:** American Ophthalmological Society annual meeting, Dana Point, CA
155. **July 11-13, 2018:** Club Jules Gonin annual meeting, Jersey, Channel Islands, UK.
156. **Aug 9-11, 2018:** DRCCR.net semi-annual summer meeting, Airport Marriott, Houston, Tx.
157. **Sept 12-15, 2018:** The Retina Society annual meeting, Palace Hotel, San Francisco, CA.
158. **Oct 26-27,2018:** Pre-AAO Retina Subspecialty Day: The art + Science of Retina + Vitreous, McCormick place, Chicago, IL.
159. **Oct 27-30,2018.** American Academy of Ophthalmology, McCormick Place, Chicago, IL.
160. **May 16-19, 2019.** American Ophthalmological Society 155th annual meeting, Greenbrier Hotel, White Sulphur Springs, West Virginia.
161. **September 11-15, 2019.** The Retina Society 52nd scientific program, The Landmark Hotel, London, UK.
162. **Oct 10, 2019.** 8th Gass Fellowship Society Meeting Le Meridien Hotel, San Francisco, CA.
163. **Oct 11, 12, 2019.** Pre-AAO Retina Subspecialty Day: Inspire Innovation, Moscone Convention Center, San Francisco, CA.
164. **Oct 12-15, 2019.** American Academy of Ophthalmology, Moscone Convention Center, San Francisco, CA.
165. **Feb 19-22, 2020.** 2020 Macula Society, annual meeting, Rancho Bernardino Inn, Rancho Bernardo, CA.

166. **Sept 2-5, 2020.** 2020 Club Jules Gonin virtual meeting.
167. **Sept 21-22, 2020.** 2020 the Retina Society, Virtual Meeting. 08:00-10:00 PM EST.
168. **Nov 13, 2020.** 2020 Pre-AAO Retina Subspecialty Day: Vision for the Future, virtual meeting.
169. **Nov 14-17, 2020.** American Academy of Ophthalmology, Virtual annual meeting.
170. **Sept 29-Oct 2, 2021.** Retina Society. Ritz Carleton, Chicago, Chicago, IL
171. **Oct-12, 2021.** ASRS annual meeting, JW Marriott Hill Country Resort & Spa, San Antonio, TX.
172. **Nov 12,13, 2021.** Pre-AAO Retina Subspecialty Day, Emerging Even Stronger, Ernest N Morial Convention Center, New Orleans, LA (pending)
173. **Nov 13-16, 2021.** AAO annual meeting. Ernest N Morial Convention Center, New Orleans, LA.
174. **May 19-21, 2022.** American Ophthalmological Society 158th Annual Meeting, Hotel Broadmoor, Colorado Springs, CO.
175. **Jun 8-10, 2022.** Macula Society 44th annual meeting, Ritz Carleton, Potsdamer Platz, Berlin, Germany.
176. **August 5-6, 2022.** DRRCR Retina Network annual summer meeting, Denver, CO.
177. **Sept 7-10, 2022.** 2022 Club Jules Gonin biennial meeting, Valamar Lacroma Hotel, Dubrovnik, Croatia.
178. **Sept 30-Oct-1, 2022.** 2022 Retina Subspecialty Day, Retina Reimagined, McCormick Place, Chicago, Ill (impending).
179. **Sept 30-Oct-3, 2022.** American Academy of Ophthalmology Annual Meeting, McCormick Place, Chicago, Ill.

180. **Nov 2-5, 2022.** Retina Society 55th Annual Meeting, Langham Hotel, Pasadena, CA.
181. **May 18-20, 2023.** 159 annual meeting of the American Ophthalmological Society, Asheville, NC.
182. **July 28-Aug 1, 2023.** ASRS annual meeting, Seattle Convention Center, Seattle Washington.
183. **Nov 2,2023.** 2023 Gass Fellowship meeting, Beacon Grand Hotel, San Francisco, CA
184. **Nov 3-4, 2023.** 2023 AAO, Retina Subspecialty Day Meeting, Moscone West Conference Center, San Francisco, CA.
185. **Nov 4-6, 2023.** 2023 AAO Annual Meeting, Moscone North and South, San Francisco, CA.
186. **Jan 27, 2024,** Doheny Eye Institute 2nd International Retina Symposium, Doheny Headquarter auditorium, Pasadena, CA
187. **Feb 7-10, 2024,** Macula Society annual meeting, La Quinta Resort and Club, La Quinta, CA
188. **May 16-18, 2024.** American Ophthalmological Society (AOS) annual meeting, Torrey Pines, The Lodge, CA 2024.
189. **May 22-25, 2024.** Club Jules Gonin annual meeting, Palma de Mallorca, Spain, May 22-25, 2024.
190. **May 31-June1, 2024.** Combined meeting of Pacific Retina Club and International Retinal Imaging Symposium annual meeting, 425 Westwood Plaza, UCLA Meyer & Renee Luskin Conference Center.
191. **September 11-15, 2024.** Retina Society annual meeting, Four Seasons Hotel, Lisbon, Portugal,
192. **October 18, 2024.** Retina Subspecialty Day, McCormick Place, Chicago, ILL, pending.
193. **October 18-21, 2024.** American Academy of Ophthalmology 2024 annual meeting, Chicago, ILL.
194. **Feb 12-15.** Macula Society annual meeting, Sunseeker, Charlotte Harbor, FL (pending).
195. **May 15-17.** American Ophthalmological Society 161st annual meeting, The Ritz-Carleton, Naples, FL(pending).

196. **June 5-7, 2025.** Combined annual meeting of Pacific Retina Club and International Retinal Imaging Symposium, UCLA Meyer & Renee Luskin Conference Center, May 31, 2024.

Clement K. Chan MD FACS

02/08/2025
